Nuclease-based editing in the porcine genome : a strategy to facilitate porcine-to human xenotransplantation by Butler, James R.
	
	
NUCLEASE-BASED EDITING IN THE PORCINE GENOME: A STRATEGY TO 
FACILITATE PORCINE-TO HUMAN XENOTRANSPLANTATION 
 
 
 
 
       
 
 
James R. Butler 
 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Medical and Molecular Genetics, 
Indiana University 
 
 
 
 
December 2017 
 
 
ii 
 
Accepted by the Graduate Faculty, of Indiana University, in partial  
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
 
 
 
____________________________ 
A. Joseph Tector, MD PhD. 
Chair 
 
 
 
 
 
____________________________ 
Kenneth E. White, Ph.D. 
Chair 
 
Doctoral Committee 
 
 
____________________________ 
C. Max Schmidt, MD Ph.D. 
 
18 April, 2017 
 
 
____________________________ 
Milan Radovich, Ph.D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
	iii 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 
James R. Butler 
 
 
 
 
 
  
	iv 
ACKNOWLEDGEMENTS 
 
I express the utmost gratitude to Dr.  A. Joseph Tector for giving me the opportunity to 
undertake the present inquiry under his guidance.  Similarly, I am thankful for the 
camaraderie, discussion and assistance provided by Dr. Greg Martens, Dr. Matthew 
Tector, Joseph M. Ladowski, Dr. Richard Sidner, Dr. Zheng-yu Wang, Dr. Luz Reyes, 
Dr. Jose Estrada, Dr. Ping Li, Dr. Rafael Santos, Dr. Andy Lutz, Dr. Ray Chihara, and 
Sue Downey.  I am indebted to my council members Drs. Kenneth E. White, C. Max 
Schmidt, and Milan Radovich, for providing invaluable counsel and direction. I am also 
grateful for support from the Indiana University Departments of Surgery and Medical and 
Molecular Genetics. This work was directly supported by Indiana University Health 
Transplant Division Department of Surgery, and grants awarded from the Association for 
Academic Surgery, and The American Society of Transplant Surgeons. Lastly, I am 
grateful for the patience and support provided by my family members.   
  
	v 
James R. Butler 
 
NUCLEASE-BASED EDITING IN THE PORCINE GENOME: A STRATEGY TO 
FACILITATE PORCINE-TO HUMAN XENOTRANSPLANTATION 
 
Solid organ transplantation is severely limited by a shortage of available donor allografts. 
Pig-to-human xenotransplantation offers a potential solution to this growing problem. For 
xenotransplantation to achieve clinical relevance, both immunologic and physiologic 
barriers must be understood. Genetic modification of pigs has proven to be a valuable 
means of both studying and eliminating these barriers. The present body of work 
describes a method for greatly increasing the efficiency and precision of genome editing 
within the porcine genome. By combining non-integrating selection and homologous 
recombination of exogenous oligonucleotides, a method for rapidly creating genetic 
modification without reliance on phenotypic sorting was achieved. Furthermore this work 
employs the technique of CRISPR/Cas9-directed mutagenesis to create and analyze 
several new animal models of porcine-to-human xenotransplantation with respect to both 
immunologic and physiologic parameters. First, Isoglobotrihexosylceramide  -a 
controversial glycan to the field of xenotransplantation- was studied in a knockout model 
and found not to affect human-anti-porcine humoral reactions. Second, a new 
combination of glycan modifications is described that significantly lowers the human-
anti-porcine humoral immune response. This model animal suggests that glycan-deletion 
alone will be sufficient to promote clinical application, and that conventional 
immunosuppression will be successful in mediating the human cellular response.  Finally, 
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two potential physiologic barriers to xenotransplantation are studied in genetically 
modified model animals. Xenogenic consumption of human platelets was studied across 
hepatic and renal organ systems; xenogenic platelet consumption was reduced by glycan 
modifications to the porcine liver while human platelet sequestration was not identified in 
the study of renal endothelium. Porcine FcRN –an essential receptor expressed in 
kidneys to maintain serum proteostasis- was studied as a final potential barrier to pig-to-
human renal transplantation. Because albumin is the primary driver of serum oncotic 
pressure, the protein-protein interaction of endogenous porcine FcRN and human 
albumin was studied. Porcine FcRN was found capable of binding human albumin under 
physiologic parameters.  In summary, the results of the present work suggest that the 
salient barriers to clinical xenotransplantation have been removed and that porcine-to-
human renal transplantation may soon offer an answer to the current organ shortage. 
 
 
  A. Joseph Tector M.D. Ph.D., Co-Chair 
                          Kenneth E White, PhD., Co-Chair 
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CHAPTER ONE:  Introduction to Xenotransplantation and Genome Modification 
	
The treatment for end stage organ failure has been transformed by solid organ 
transplantation. Unfortunately today, a growing shortage of donor allografts severely 
limits the reach of this treatment. The solid organ waitlist has over 180,000 patients in the 
United States, and each year this number continues to grow, matched against a relatively 
static supply of available organs for transplant (Figure 1.1).  Every 14 minutes, someone 
is added to the renal transplant list alone. Not considering those patients that are deemed 
too sick to be placed on the waiting list, 13 patients die each day while waiting for a 
kidney transplant.   Xenotransplantation, the transplantation of organs across species, has 
been proposed as a potential solution to this growing problem. Owed to certain 
gestational, immunologic and physiologic properties, pigs have been identified as the best 
potential surrogate organ donor. However, for pig-to-human xenotransplantation to be 
realized as a treatment, several important immunologic and physiologic barriers must be 
studied and overcome. Genetic modification of porcine models has proven valuable to the 
study of porcine-to-human xenotransplantation. Recent advances in genetic engineering, 
coupled with somatic cell nuclear transfer has greatly sped up the process of model 
animal creation. Moving from model to treatment will require improvements to the 
efficiency and precision of these tools; this is a central pursuit in the present body of 
work.  
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Figure 1.1: The growing gap between Unites States solid organ waitlist patients and 
available organs. 
	
The gap between available organs for transplant and patients on the solid organ transplant 
list has existed since the beginning of organ transplantation. Despite attempts to utilize 
available solid organs more liberally, this gap continues to grow. Today there are more 
than 180,000 patients on the transplant waitlist in the United States alone; for many 
patients each day this will mean death without transplantation. Not captured in these 
figures are the many patients evaluated at transplant centers but unlisted due to 
prioritization of healthier recipients in the face of systemic organ shortages.   
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CRISPR/Cas9 Nuclease 
Though genetic engineering has a long history, the present work is uniquely indebted to 
the CRISPR/Cas9 platform of genome modification; as such, these tools are deserving of 
a dedicated introduction. Few scientific revolutions have offered greater potential to both 
research and therapy than the advent of CRISPR genome-editing. CRISPR gene-targeting 
represents three advantages relative to previous tools. First, the flexibility in target-design 
coupled with recent advances in genomic sequencing allows for unparalleled ease in 
gene-targeting. Second, CRISPR allows investigators to effect multiple site-specific 
alterations concurrently. Third, the versatility of the platform offers a wide repertoire of 
effects to achieve complete control over the targeted loci.  The potential applications of 
CRISPR-engineering range from plants to animals, infectious disease to cancer. At the 
most elemental level, CRISPR has sped the pace of creating new animal models for the 
study of human disease. Moving quickly from model to potential treatment, pig-to-human 
xenotransplantation offers one of the most immediate opportunities for clinical 
application of this technology: an answer to the growing shortage of available organs for 
transplant.  
 
The origins of CRISPR 
Since its recent discovery, CRISPR technology has steadily been distinguishing itself as 
the greatest medical breakthrough to come from prokaryotes since Alexander Fleming 
noticed a contaminant strain of Penicillum notatum clearing Staphylococcus cultures. 
With an equal amount of serendipity, CRISPR can trace its prokaryotic origins to a 
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Danish yogurt company. There, scientists were working to promote viral resistance in 
Streptococcus thermophilus, a bacterium needed for yogurt production; they observed 
that short palindrome sequences -mirror images within the DNA separated by a short 
spacing sequence- provided acquired immunity against foreign genetic elements. In 
bacteria, foreign DNA is digested and inserted into the CRISPR locus, from which 
CRISPR RNA (crRNA) is made.[1] These short RNA sequences then associate with 
homologous –presumably foreign- sequences in the genome. When the homologous 
genomic sequence is followed by an appropriate ‘protospacer-adjacent motif’ (PAM) at 
the 3’ end, the Cas9 endonuclease creates a DSB. (Figure 1.2 A1) The PAM spacer helps 
prevent the CRISPR-locus itself from being targeted.[2]  In 2007 they published their 
findings that clustered regularly interspaced short palindromic repeats (CRISPR) and 
CRISPR-associated proteins [Cas] were adaptable agents of prokaryotic immunity. [3]  
Over the next several years in laboratories across the world, the mechanisms of 
this system underwent a series of pivotal discoveries that would help recognize CRISPR 
as a potential agent of DNA manipulation. [4-8] In August of 2012 the CRISPR/Cas9 
system was realized as a programmable platform for targeted genome editing.[9] By 
February of the following year, CRISPR/Cas9 was successfully used to introduce 
targeted genetic manipulation in a range of mammalian species, including the human 
genome.[10] 
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The path towards gene-targeted animals 
CRISPR/Cas9 technology currently represents the most advanced method of effecting 
genetic alteration; its importance is best understood in context with the recent history of 
mammalian genome editing. Capecchi, Smithies, and Evans first developed methods to 
create targeted alterations in the mouse genome more than 20 years ago.[11] By 
discovering that mammalian cells could incorporate exogenous DNA into their genome 
through a process of homologous recombination, they were able to produce the first site-
specific mutations. Although tedious –about 1 in 1,000 attempts would succeed[12]- this 
process represented a paradigm shift for somatic cell genetics. When these results were 
reproduced in embryonic stem cells (ES), followed by injection of modified cells directly 
into a pre-implanted blastocyst, the first gene-targeted mice were created.  
Pigs offer multiple advantages over mice as models for human research due to 
their morphologic, physiologic, immunologic and gestational properties.[13, 14] 
Similarly, pigs have been identified as the most suitable surrogate for human allografts in 
Xenotransplantation.[15] Unfortunately porcine ES cells are not available.[16] Because 
of this -and the supposition that somatic differentiation was unidirectional- the creation of 
gene-targeted pigs was considered impossible. This barrier was eliminated in 1997 when 
a mammary epithelial cell was fused with an enucleated egg.  By this process, a somatic 
cell metamorphosed into an embryonic cell capable of producing a cloned sheep.[17] 
This process of somatic cell nuclear transfer (SCNT) has now become of central 
importance to the field of xenotransplantation. In the continued absence of reliable pig 
embryonic stem cells, gene-targeted pigs are created from modified somatic cells. In 
2000, SCNT produced the first wild-type clonal pigs;[18] two years later, the first gene-
	6 
targeted pig was cloned from cells edited by the same process of homologous 
recombination that had been used to create model mice.[19]  
  
	7 
Early nuclease technology  
Site-specific endonuclease technology actually predates the CRISPR/Cas9 system by 
several years and began shifting attention away from homology-driven gene targeting by 
2002.[20] Endonucleases are DNA-cutting enzymes that create a double strand break 
(DSB) in DNA. Nuclease-driven DSBs are subsequently repaired by non-homologous 
end joining (NHEJ). Because NHEJ is a relatively low fidelity process, the repaired DNA 
often includes small insertions or deletions that result in a null phenotype. By artificially 
tethering an endonuclease to sequence-specific DNA binding proteins such as 
transcription activator-like effectors or zinc-fingers, targeted genetic mutation could be 
delivered to the mammalian genome.[21] In 2011 zinc-finger nucleases  (ZFNs) were 
utilized to create true knockout pigs in 5 months instead of 36 months.[22] 
The discovery of CRISPR/Cas9 as a naturally occurring sequence-targeting 
nuclease system offers an opportunity to capitalize on efficiencies forged over millions of 
years in bacterial evolution. In bacteria, foreign (viral) DNA is digested and inserted into 
the CRISPR locus, from which CRISPR RNA (crRNA) is transcribed. Short crRNA 
combine with trans-activating RNA which then act as mobile guides that scour the entire 
genome for their DNA homologs, marking unwanted viral inserts. When the homologous 
genomic sequence is followed by an appropriate 3’ protospacer-adjacent motif (PAM), 
the Cas9 endonuclease is recruited and creates a DSB. The most commonly used system 
originates from Streptococcus pyogenes, which has a 3’ PAM sequence of NGG, where 
N represents any nucleotide.[9] This system allows for the creation of a mutation event in 
any porcine genomic sequence consisting of GN19NGG. This process may be 
reappropriated to target any loci in any genome by simply introducing exogenous guide 
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RNA sequences together with Cas9 to the nuclei. In this way, genome-editing has quickly 
become fast, reliable and affordable.   
 
CRISPR at work 
Applications of the CRISPR platform for genome editing are now pervasive. The use of 
tissue-specific promoters to drive Cas9 expression allows CRISPR to target virtually any 
loci in a tissue-specific manner. Recently, cardiac-specific[23] and lung-specific21 
applications have been described, this will allow for the rapid creation of new models of 
heart and lung disease. Coupled with the plasticity of CRISPR gene-targeting, this may 
eventually offer a method to achieve targeted and sustained control of even the most 
challenging genetic problems, like the heterogeneous nature of pancreatic or non-
squamus cell lung carcinomas.  
Today, one of the most immediate applications for CRISPR technology is pig-to-
human xenotransplantation. As new models move closer to clinical relevance, CRISPR-
modified pigs now offer a potential answer to the single largest problem facing the field 
of transplantation: a growing shortage of transplantable organs. CRISPR technology has 
greatly sped the process of creating genetically modified pigs. In 2014, CRISPR was used 
to silence 3 separate porcine genes in a single reaction, creating pigs of multiple genetic 
modifications within a single pregnancy.[24] Later that year, a Class 1 MHC-null pig was 
created, representing the simultaneous silencing of 7 porcine alleles within a single 
reaction.[25]  The number of concurrently targeted loci within the porcine genome has 
since increased as high as 62.[26] CRISPR’s ability to efficiently target multiple loci has 
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also facilitated the recent discovery of triple-gene knockout pigs that exhibit very low 
levels of human antibody binding.[27] As described within the present body of work, 
measures of human-anti-porcine humoral immunity can now be reduced to levels 
comparable with allograft transplantation;[28] clinical xenotransplantation is closer than 
ever. Although the full potential of CRISPR genome-editing is almost certainly not yet 
realized, it represents a technology worth watching for both researchers and clinicians.  
 
Evolving strategies of porcine gene-modification  
A central hypothesis of the present work is that gene-knockout pigs hold great promise 
for creating donor animals that will be suitable for clinical xenotransplantation.  
Specifically, this work privileges the study of gene-modifications that affect the porcine 
glycome. The immunologic potential of carbohydrate profiles has been recognized since 
the early 1900s when De Landsteiner received the Nobel Prize for characterizing ABO 
blood groups in his study of allogenic blood transfusion. Later understood to be driven by 
the ABO glycosyltransferase on chromosome 9q34.1, this enzyme creates glycoproteins 
that are among the most important antigens in allograft matching. Because these 
glycosyltransferases imprint many proteins through post-translational modification their 
immunologic significance is leveraged.  Similarly, species-specific glysylation patterns 
have the potential to create powerful sources of xenoantigens that –if unmodified- would 
prohibit successful xenotransplantation. The present work recognizes the importance of 
two important carbohydrate xenoantigens to which humans have xenoreactive antibodies: 
gal-α-(1,3)-gal, and N-glycolylneuraminic acid (Neu5Gc).  These xenoantigens are 
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produced by enzymes that are present in humans and pigs, but in humans, gene activity 
has been silenced during the course of evolution.  α-1,3-galactosyltransferase (GGTA1) 
produces the Gal α(1,3) Gal epitope, and the development of GGTA1-/- pigs eliminated 
70-85% of the xenoreactive antibodies that humans have as a barrier to 
xenotransplantation.  The cytidine monophosphate-N-acetylneuraminic acid hydroxylase 
(CMAH) gene produces N-Glycolylneuraminic acid (Neu5Gc).  The creation of GGTA1-
/- CMAH-/- pigs has further reduced human antibody binding to the point where the 
crossmatch of pigs with humans is more favorable than a primate-to-human crossmatch. 
[29] As described later in the present body of work, the CRISPR/Cas9 system has now 
been used to simultaneously silence 3 glycome-modifying porcine genes; the majority of 
humans now exhibit very low levels of antibody binding to cells from this triple knockout 
pig. 
Although it is our belief that the present findings will help solidify the clinical 
relevance of carbohydrate knockout models, this approach has not always been favoured 
by the field. As aforementioned, the creation of gene-targeted pigs has traditionally been 
slow and tedious because of the lack of identifiable embryonic stem cells (ES) in the pig, 
the reliance upon homologous recombination to create targeted gene deletions, and the 
subsequent need for lengthy breeding programs to create homozygous knockout pigs. In 
this climate it was difficult to efficiently create true knockout animals. Because of these 
barriers, human transgene delivery into the porcine genome has been the dominant 
strategy of pig-to-human xenotransplantation research. The difficult road towards 
efficient porcine knockout model creation is best understood by examining recent 
strategies to remove the first-discovered porcine xenoantigen: αGal (GGTA1). 
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Random Integration 
Initially, due to the absence of pig ES, creating a true genetic knockout pig was not 
feasible. In this era, attention focused on transgenic methods to regulate αGal expression. 
The process of ‘competitive glycosylation’ involved inserting a gene for a 
fucosyltransferase or sialyltransferase; [30] by depleting the common acceptor substrate 
N-acetyllactosamine, αGal was competitively replaced with less immunoactive 
oligosaccharides. At the genomic level, one such method placed a human cDNA 
fucosyltransferase -under CMV and H2K-b promoters- into the pig genome by embryo 
microinjection. [31] Despite variable and mosaic expression patterns, this method was 
successful in reducing αGal expression.     
 
Somatic Cell Nuclear Transfer  
One of the early barriers to creating genetically modified pigs was the biologic tenant that 
cellular differentiation is unidirectional. This dogma was rewritten in 1997 when a 
mammary epithelial cell was used to create an embryonic cell. [17] Fused with an 
enucleated egg, a somatic sheep cell was redesigned to become an embryonic cell capable 
of producing a cloned sheep. This process of somatic cell nuclear transfer (SCNT) has 
now become of central importance to the field of xenotransplantation. In the absence of 
pig embryonic stem cells, genetically modified pigs are created directly from somatic cell 
modification; by 2000, SCNT was successfully used to clone pigs. [18, 19]  
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Homologous Recombination  
With new ability to create clonal animals from somatic cell nuclear donors, the field 
shifted focus from microinjection of randomly integrating transgenes towards site-
directed mutagenesis. The first of these gene-targeting strategies was homologous 
recombination (Figure 1.2B). In 2002, Lai et al used a gene trap-targeting vector, 
pGalGT, for homologous replacement of the endogenous GGTA1 allele;[19] after 
antibiotic selection and SCNT, 4 single-allele knockout pigs were created. Later that 
year, Phelps et al. accelerated the production of a double αGal knockout pig by 
employing three consecutive rounds of cloning instead of backcross breeding.[32] In this 
process, heterozygous fetal fibroblasts were isolated from a pregnancy and subjected to a 
second ATG-targeting knockout vector with antibiotic selection. After enrichment for 
αGal - cells by C. difficile toxin A, the second allele was found to be serendipitously 
disrupted by a rare spontaneous mutation. Aside from this one spontaneous mutation, 
antibiotic selection markers complicated homologous recombination strategies; the 
obligatory insertion of exogenous genes of antibiotic resistance limited clinical 
application of these animals.  
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Figure 1.2: Gene Knockout strategies.  
	
A depicts site-specific nuclease-based editing tools. A1: CRISPR targets Cas9 to create a 
double stranded break. A2: The Nickase system targets a mutant Cas9 to create two 
adjacent single-strand breaks. A3: TALENs dimerize two FokI units to create a double 
strand break. A4: Zinc Fingers similarly dimerize two FokI units to create a double strand 
break. B depicts homologous recombination technique. A donor plasmid is built with 
homologous arms flanking an exogenous selection marker. C depicts the resulting 
mutation events. DSBs are repaired by error-prone NHEJ to create variable-length 
insertions or deletions. This may simultaneously affect both alleles. Homologous 
recombination targets cell division, where the donor plasmid homology arms cross over 
with the genomic DNA, disrupting the loci by inserting an exogenous marker. D Somatic 
cell nuclear transfer (SCNT) uses the mutated cell to create a clonal animal. E Due to low 
	14 
efficiency, HR most often affects one allele, while with appropriate selection, nuclease-
based approaches may create a biallelic knockout within a single reaction.   
 
Nuclease Editing  
Site-specific nuclease technology shifted attention away from homology-driven 
recombination knockout. Table 1.1 compares the 4 nuclease classes. Broadly speaking, 
these strategies involve creating a double-strand break (DSB) by targeting a bacterial 
nuclease to a specific genomic sequence. Nuclease-driven DSBs are subsequently 
repaired by the error-prone process of non-homologous end joining (NHEJ). The product 
often includes small deletions or insertions that yield missense or nonsense mutations and 
a null phenotype. (Figure 1.2C-E) Alternatively, homology-directed repair (HDR) offers 
the opportunity to control the mutation event.[33] By co-transfecting a site-specific 
nuclease with oligonucleotides or donor sequences containing locus-specific homology to 
the DSB site, a specific insertion may be created.[34] Regardless of repair pathway, the 
introduction of DSBs can increase the random recombination frequency from 1 event per 
10^6 cells to 1 in 5 cells.[35]  
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Table 1.1:  Nuclease Classes 
	
 ZFNs TALENs CRISPR Nickase 
Nuclease FokI FokI Cas9 mCas9 
gDNA Targeting 
Mechanism 
Zinc-finger 
protein 
Transcription 
activator-like 
effector sgRNA sgRNA 
Target Design 
Requirements G-rich 
Begin with T; 
end with A GN19/NGG 2(GN19/NGG) 
Specific Length of 
Target Site 18-36 bp 30-40bp 22bp 22bp 
Mutation Rate* 
Low  
(10%) 
High  
(20%) 
High  
(20-75%) 
High  
(20%) 
Off-target Effects High Low Variable** Very Low 
Cytotoxicity High Low Variable Very Low 
Size 1KB 1KB 4.2KB 4.2KB 
Commercial Cost 
per Target  
$4,000-
7,000 $3,3600-$5,000 $500  $500  
 
ZFN, zinc-finger nuclease. TALEN, Transcription activator-like effector nuclease. 
CRISPR, clustered regularly interspaces short palindromic repeat. Cas9, CRISPR-
associated protein 9. gDNA, genomic DNA. sgRNA, single guide RNA. N, any 
nucleotide. *Mutation rates reported are variable across the literature and depend on cell-
type and delivery method, they are commonly defined as the frequency of insertion or 
deletion without respect to phenotype. ** CRISPR/Cas9 off-target rates may be 
controlled during the design of sgRNA targets by bioinformatics query against the 
genome of interest.[36] Commercial cost calculated based on Biocompare data 
(Biocompare, San Franciso, CA. USA). 
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Zinc Finger and TALEN Nuclease  
In 2010, Zinc Finger Nucleases (ZFN) offered the first of the site-directed approaches 
used in the porcine genome. [37] ZFNs are fusions of a nonspecific DNA cleavage motif 
with a sequence-specific zinc finger protein. (Figure 1.2A4) The nuclease activity is a 
derivative of the FokI bacterial restriction endonuclease, capable of creating a single 
strand break. ZFNs operate in concert by dimerizing two DNA-binding domains with two 
FokI enzymes to produce DSBs with 18bp targeting specificity. The subsequent damage 
response pathway of NHEJ afford ZFNs their mutagenic potential. (Figure 1.2C) In 2013 
ZFN were used to create a biallelic knockout of both the αGal and CMAH genes in vitro 
prior to SCNT; this set an important precedent of using endonuclease technology to 
remove two xenoantigens from a wild-type genome within 7 months.[38] 
Transcription activator-like effector nucleases (TALENs) were introduced to the 
porcine genome in 2011, and function like ZFNs to create DSBs by tethering the FokI 
endonuclease to DNA binding domains.[39] (Figure 1.2A3) In 2013, TALENs were used 
to create biallelic GGTA1 knockout pigs. In this process, the targeting efficiency of 
TALEN-directed mutagenesis has been reported with efficiencies reaching 73.1% with a 
27.8% rate of biallelic knockout.[40] TALENs may be distinguished from ZFNs by their 
ease of design, decreased cost, and marginally improved targeting frequencies.   
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Off-target effects   
Understanding the potential for off-target effect of nuclease-based genomic editing is 
essential as new porcine models become clinically relevant. An off target effect is created 
when a mutation event occurs outside the targeted locus. Early recognition of this 
phenomenon began with ZFN-cytotoxicity, presumably caused by target sequence 
homology to multiple and unintended loci. Because the active ZFN is a dimer with each 
3-Finger side recognizing 9 bps, the combination should recognize a unique 18bp 
sequence. However, due to symmetry at the FokI interface, homodimerization is possible, 
which reduces the specificity to 9bp. [35] Successful strategies to avoid this have been 
adopted and include an altered FokI incapable of homodimerization and the creation of a 
highly-specific 5-finger ZFN. [41] Conversely, it has recently been suggested that 
shortening the guide RNA molecule for Cas9 may increase CRISPR site specificity.[42] 
A second approach to limiting off-target endonuclease effect is the adoption of 
ZFN and Cas9 Nickases. By inactivating one of the ZFN monomers or mutating Cas9, 
Nickase strategy relegates the endonuclease capable of inflicting only single strand 
breaks.[43, 44] In both scenarios, the resulting single strand break favors the HDR repair 
pathway over NHEJ. Because single strand breaks are often repaired without error, off 
target hits are overwhelmingly silent.[45] Nickase-driven mutagenesis remains possible 
by co-transfecting a ZFN nickase with a homologous oligonucleotide or co-localizing 
two independent Cas9-nickases. (Figure 1.2 A2)  Off-target limits for CRISPR/Cas9 
sgRNA can be incorporated into the design process by using bioinformatics to query 
possible off-target binding sites; avoiding guide sequences that bind to multiple regions 
within the genome and limiting possible off-targets to non-coding regions can 
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significantly reduce background.[36] Even in the absence of these specificity-enhancing 
techniques, recent studies employing whole-genome sequencing suggest very low rates of 
off-target effects of conventional endonuclease technique.[46] Importantly, off-target 
effects have not limited the ability to employ nuclease based editing tools for the creation 
of healthy donor animals through SCNT.  
 
Nuclease-based transgene delivery  
As reported later within the present work, nuclease-created DSBs also have the ability to 
facilitate efficient transgene delivery. By co-transfecting a site-specific nuclease with an 
exogenous gene flanked by locus-specific homology arms to the DSB site, an exogenous 
sequence may be successfully inserted. (Chapter Two) This combines the initial process 
of HR with modern nuclease-based editing to exponentially increase both the frequency 
and specificity of transgene insertion. Where once, a randomly integrated transgene was 
the only tool, nuclease-based techniques now offer simultaneous ability to insert and 
delete genetic material. Genetic engineering has transitioned from random addition of 
genes and expression cassettes to site-specific deletion or addition of genetic material.  
The pace of genetic engineering has changed rapidly over the past five years. 
Understanding the capability of nuclease-based editing has led to a dramatic increase in 
the productivity of our field. As displayed in Table 1.2, the published numbers of 
genetically unique animals is increasing dramatically. Where once it took 36 months to 
create a biallelic knockout animal, multiple-gene knockout animals can be reliably 
produced within 6 months.[47]  These tools have brought xenotransplantation closer to 
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the clinic than it has ever been. Described within the present work, a triple knockout 
animal has now been created that exhibits a negative antibody-mediated complement-
dependent crossmatch on the majority of patients currently on a solid organ waitlist 
(Chapter Four).  One of the greatest achievements in transplant medicine was the early 
adoption of calcineurin inhibitors; by controlling the early immunologic injury, it 
revolutionized allotransplantation into a reliable treatment. The central aim of the present 
body of work is that we may soon come to recognize nuclease-based genetic engineering 
as the catalyst that turns xenotransplantation into a clinical reality.  
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Table 1.2: The creation of pigs carrying unique genetic alterations.  
	
First Author 
(Year) Modification Technique 
Fodor (1994) [48] Human CD59 + 
Random integration (H2kb-
hCD59 DNA for embryo 
injection) 
Cozzi (1995) [49] Human CD55 + 
Random integration (6.5 
kilobase DNA construct with 
the 4kb hDAF) 
Osman (1997) [50] Human GLA + 
Random integration (pH2kb-
hHT) 
Costa (1999) [31] Human H-transferase + 
Random integration (H2Kb-
HT construct) 
Diamond (2001) 
[51] Human CD46 + 
Random integration (60kb 
genomic construct with 
CD46) 
Miyagawa (2001) 
[52] Human GnT-III + 
Random integration (pCX 
vector-GnT-III) 
Lai (2002) [19] GGTA1 -/+ Homologous recombination 
Phelps (2003) [32] GGTA1 -/- 
Homologous recombination, 
back cross 
Klose (2005) [53] Human TRAIL + 
Random integration (TRAIL 
in pUCH2XXS-TRAIL) 
Wu (2007) [54] Human DAF and MCP + Random integration 
Dieckhoff (2008) 
[55] PERV siRNA 
Random integration 
(pLVTHM-pol2 with 
shRNA) 
Phelps (2009) [56] Porcine CTLA4-Ig + 
Random integration 
(pCTLA4-Ig with CHS and 
CH3 linker of IgG1) 
Peterson (2009) 
[57] Human thrombomodulin + 
Random integration (hTM in 
pEGFP-N1) 
Weiss (2009) [58] 
HLA-E/Human Beta-2-
microglobulin + 
Random integration (HLA-
B7 in pCR2.1-TOPO) 
Oropeza (2009) 
[59] Human A20 + 
Random integration 
(pCAGGSEhA20-IRESNEO) 
Yazaki (2009) [60] 
Endo-B-Galactosidase + and 
Human CD55 + 
Random integration (pCAG-
hDAF-p(A)) and 
(pCAGGS/GT+EdnoGalC-
neo) 
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Hara (2010) [61] CIITA-DN + Random integration  
Seol (2010) [62] Human Fas Ligand + 
Random integration 
(pcDNA/FasL) 
Cho (2011) [63] Human TNFRI-Fc + 
Random integration 
(shTNFRI-Fc) 
Yeom (2012) [64] Human heme oxygenase 1 + 
Random integration (SV40-
hHO-I) 
Wheeler (2012) 
[65] Human CD39 + 
Random integration (H2Kb-
hCD39) 
Klymiuk (2012) 
[66] LEA29Y + 
Random integration 
(LEA29Y in B-cell specific 
expression vector) 
Lutz (2013) [38] GGTA1-/- CMAH -/- ZFN 
LI (2014) [47] 
GGTA1 -/- CMAH -/- IGb3S -
/- CRISPR/Cas9 
LI (2014) [47] GGTA1 -/- CMAH -/-  CRISPR/Cas9 
LI (2014) [47] GGTA1 -/- CRISPR/Cas9 
LI (2014) [47] GGTA1 -/-  IGb3S -/- CRISPR/Cas9 
Reyes (2014) [25] GGTA1-/-; SLA-1,-2,-3 -/- CRISPR/Cas9 
Paris (2015) [67] ASGR1 -/- TALEN 
Estrada (2015) [24] 
GGTA1-/- CMAH-/- 
B4GalNT2 -/- CRISPR/Cas9 
 
+ denotes transgene expression. -/- denotes biallelic knockout.  -/+ denotes 
heterozygote knockout.  
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CHAPTER TWO: Efficient generation of targeted and controlled mutational events 
in porcine cells using nuclease-directed homologous recombination. 
	
INTRODUCTION  
	
As discussed within the previous chapter, the clustered randomly integrating spaced 
palindromic repeats and associated Cas9 protein (CRISPR/Cas9) platform has 
revolutionized the process of creating targeted genetic modification. Capitalizing on the 
error-prone nature of DNA repair, CRISPR-targeted DNA damage delivers phenotype-
altering insertions and deletions. When coupled with the success of somatic cell nuclear 
transfer (SCNT), this has produced the ability to efficiently create model organisms at an 
unprecedented pace.[21] Improvements in the efficiency and precision of this platform 
will increase our ability to develop novel clinical applications. These techniques also hold 
great promise for the future of clinical xenotransplantation and cell-based therapies for 
cancer or immunodeficient pathology. However, to fully realize the potential of nuclease 
editing tools, the efficiency and precision of their application must be optimized. 
Recent success using nuclease editing to efficiently create new model swine has 
relied on a phenotypic selection strategy of genetically modified cells for use in animal 
cloning that involves somatic cell nuclear transfer.[24, 47]  Occasionally, cell types that 
are useful in animal cloning cannot be selected on the basis of the desired phenotype; 
these lines ultimately require genomic analysis to isolate the desired mutants.  In this 
territory, even small improvements in efficiency can reduce the time and cost of 
identifying appropriately modified cells. To this end, the targeted introduction of 
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restriction enzyme binding sites into the genome offers an important selection tool; 
restriction digest of clonal cell populations can reliably identify genomic modification.  
Herein we describe a process by which nuclease-driven genomic editing in pigs 
can be enhanced by a non-integrating selection strategy. We describe the introduction of 
short exogenous DNA sequences to offer control over the mutational event and aid in 
genotype selection. Furthermore, we show that the use of very short 5’ homology 
sequences can affect locus-specific transgene delivery to the porcine genome. These 
methods increase the precision and efficiency of nuclease-based genome editing. Their 
application will aid broadening applications for nuclease technology by unfettering their 
use from phenotypic selection. 
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MATERIALS AND METHODS  
 
Porcine aortic cell isolation and culture 
 The animals used in this study were approved by the Institutional Biosafety and 
Institutional Animal Care and Use Committee of Indiana University School of Medicine. 
Porcine primary aortic endothelial cells (AEC) were isolated from wild-type porcine 
aorta after euthanasia. The posterior lumbar arteries were ligated and the aortic lumen 
was filled with 0.025% of collagenase type IV from Clostridium histolyticum (Sigma, St. 
Louis, MO), placing vascular clamps on proximal and distal ends. This sample was 
incubated at 37 °C for 35 min. Enzyme activity in the perfusate was immediately 
quenched by the addition of 1/10 volume new born calf serum. The perfusate was 
centrifuged at 400 g for 10 min at room temperature. The cell pellet was saved and 
resuspended in RPMI medium supplemented with 0.02% (w/v) EDTA. The cell 
suspension was centrifuged again at 400 g for 10 min at 4 °C. The pellet was resuspended 
in EC culture medium (RPMI medium supplemented with 10% fetal bovine serum (v/v), 
100 µg/ml endothelial cell-specific growth factor, penicillin, streptomycin, and 
amphotericin B). After seven days, endothelial cells were purified from culture by 
staining with chicken anti-Pig CD31 (Invitrogen, Grand Island, NY) and positive sorting 
using a FACS Aria II (Becton Dickinson, San Jose, CA). 
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Creation of an immortalized AEC line.  
Porcine immortalized cell lines were generated as described previously [68]. Briefly, 
primary AECs from domestic pigs were isolated as described above. After a 3-day 
culture, AECs were infected for 24 hours with lentiviral supernatant, containing lentiviral 
vector in which a c-DNA expresses the large and small T antigen of SV40 (Applied 
Biological Materials Inc, Richmond, BC, Canada). Single-cell clones were isolated and 
amplified. 
 
Cas9 guide RNA and DNA oligonucleotide assembly  
The clustered randomly interspaced palindromic repeats and associated protein 9 
(CRISPR/Cas9) nuclease system was employed to introduce targeted double strand 
breaks (DSB) within the porcine genome. A single-guide RNA was designed to target the 
porcine GGTA1 gene beginning at position 293654066 of NC_010443.4. A pair of 
oligonucleotides for the targeted site were designed and checked using ZiFiT Targeter 
Version 4.2 software (http://zifit.partners.org/ZiFiT/). These oligonucleotides (forward: 
5’CACCGAGAAAATAATGAATGTCAA3’, reverse: 5’AAACTTGACATTCATTA-
TTTTCTC3’) were annealed to generate short double-strand DNA fragments which were 
ligated to BbsI-linearized Cas9 vectors pX330-U6-Chimeric_BB-CBh-hSpCas9 or 
pSpCas9[14]-2A-GFP plasmids which were a gift from Feng Zhang (Addgene plasmid 
#42230 and 48138 respectively).[10, 69]  
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Transfection and cell sorting by non-integrating selection 
Porcine AECs were transfected by electroporation using the Neon transfection system 
(Life Technologies, Grand Island NY, USA) according to the manufacturer’s instruction. 
Concentrations of Cas9-expressing plasmid and cell number remained constant at 
2ug/1e6 cells per transfection. Cas9 expression vectors differed only by the presence or 
absence of GFP. Cells were cultured for 24 hours in antibiotic free culture media. After 
24 hours, cells transfected with a GFP expressing vector were sorted for fluorescence 
using a FACS Aria II (Becton Dickinson, San Jose, CA). A gate was established to retain 
the brightest cells; this was limited to <3% of the total population. All cells were retained 
in culture for 14 days after sorting, at which point the absence of transient GFP 
expression was confirmed in the experimental group by flow cytometric analysis using an 
Accuri C6 flow cytometer (Accuri, Ann Arbor, MI, USA).  For comparison, a column 
selection strategy was simultaneously employed as described by Li et al.[24] Briefly, this 
approach involved co-transfection with CRISPRs designed to inactivate both the CMAH 
and GGTA1 genes without a GFP selection, followed by column selection with anti- 
Neu5Gc antibody (Sialix, Vista, CA, USA) on day 14, to remove Neu5Gc (CMAH gene 
product) positive cells; the effect on GGTA1 gene mutation was then observed.    
 
Analysis of phenotype-specific mutation efficiency.  
The phenotype-specific mutational efficiency was analyzed by measuring expression of 
the Galα(1,3)Gal epitope (GGTA1 gene product). Cells were stained with Alexa Fluor 
488 conjugated Griffonia simplicfolia IB4 (Invitrogen, Grand Island, NY, USA) to 
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examine gene expression function. Unlabeled cells were used as a negative control. Flow 
cytometric data were collected using Accuri C6 flow cytometer (Accuri, Ann Arbor, MI, 
USA), analysis was performed with FlowJo software version 8.8.7 (Treestar Inc., 
Ashland, OR). 
 
Analysis of genotypic mutation efficiency 
Cells were analyzed to determine genotypic mutation efficiency at a second porcine locus 
by sequencing of clones after nuclease delivery and cell sorting by fluorescence. To show 
the applicability of our strategy across loci, a second porcine locus was targeted for this 
analysis. A gRNA sequence was designed to target the FGL2 gene beginning at position 
113115686  of NC_010451.3 ( 5’-GAAGCTGTCGAACTGGTGC-3’). Porcine AECs 
were transfected by electroporation using the Neon transfection system (Life 
Technologies, Grand Island NY, USA) according to the manufacturer’s instruction. 
Concentrations of Cas9-expressing plasmid and cell number remained constant at 
2ug/1e6 cells per transfection. Cas9 expression vectors differed only by the presence or 
absence of GFP. Cells were cultured for 24 hours in antibiotic free culture media. After 
24 hours, cells transfected with a GFP expressing vector were sorted for fluorescence 
using a FACS Aria II (Becton Dickinson, San Jose, CA). A gate was established to retain 
the brightest cells; this was limited to <3% of the total population. Individual cells from 
the retained population were expanded clonally and genomic DNA was obtained from 
each colony using a GeneElute Mammalian Genomic DNA Miniprep Kit (Sigma-
Aldrich, St. Louis, MO, USA). Polymerase chain reaction amplification of the targeted 
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region for analysis was accomplished using the primers: forward 5’-
CCCGCCCTTTTCTGAGAACA-3’, reverse 5’-GGTGACAGCAGTCCATTCCT-3.’ 
Pwo SuperYield DNA polymerase (Roche Applied Science, Indianapolis, IN, USA) was 
used, and PCR conditions for GGTA1 were as follows: 94 °C, 2 min; 94 °C, 15 s; 54.7 
°C, 30 s; and 72 °C, 30 s for 15 cycles; 94 °C, 15 s; 54.7 °C, 30 s; 72 °C, 30 s with 
additional 5 s each cycle for 25 cycles; and a final extension step of 72 °C for 5 min. 
Sequence was analyzed by Sanger reaction.  
 
HDR-directed mutagenesis 
In the context of improved nuclease-directed mutation efficiencies, we endeavored to test 
whether we could use exogenous DNA oligonucleotides to facilitate nuclease-mediated 
HDR in porcine aortic endothelial cells. DNA oligonucleotides for short HDR were 
designed with homology to the genomic sequence at the nuclease-targeted cut site. Single 
strand DNA (ssDNA) oligomers were designed with homology to the genomic sense 
(forward) and antisense (reverse) strand. Total length of HDR oligos were 30bp and 50 
bp. Double-strand DNA (dsDNA) was created by annealing sense and antisense 
oligomers. In all sequences, the translation start codon was replaced with EcoRI 
restriction enzyme to facilitate downstream analysis.  In addition, single-stranded RNA 
oligonucleotide was designed analogous to the 50bp sense homology sequence. All 
oligonucleotides were ordered from Integrated DNA technologies (Coralville, Iowa, 
USA). At the time of nuclease-delivery, exogenous template DNA was delivered at either 
a 1uM or 5uM concentration. Cells were kept in culture for 14 days at which point they 
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were analyzed and sorted for phenotypic mutation events. Mutation-positive cells were 
retained and expanded clonally. 100 clones from each experimental group were obtained 
for genomic analysis.  
 
Analysis of HDR-directed genome editing. 
Genomic DNA was isolated from clonal cultures of mutated cells using a GeneElute 
Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich, St. Louis, MO, USA). 
Polymerase chain reaction amplification of the targeted rejoin for analysis was 
accomplished using the primers: forward 5’-CCTTAGTATCCTTCCCAACCCAGAC-3’, 
reverse 5’-GCTTTCTTTACGGTGTCAGTGAAT-3.’ Pwo SuperYield DNA polymerase 
(Roche Applied Science, Indianapolis, IN, USA) was used, and PCR conditions for 
GGTA1 were as follows: 94 °C, 2 min; 94 °C, 15 s; 54 °C, 30 s; and 72 °C, 45 s for 15 
cycles; 94 °C, 15 s; 54 °C, 30 s; 72 °C, 45 s with additional 5 s each cycle for 25 cycles; 
and a final extension step of 72 °C for 5 min. HDR-directed editing efficiency was 
determined by restriction digestion and confirmed by sanger sequence. HDR templates 
were designed to introduce an EcoRI restriction site at the GGTA1 transcription start site; 
successful HDR was confirmed with EcoRI restriction enzyme digestion and 
subsequently verified by sanger sequence. GraphPad Prism 5 (GraphPad Software, La 
Jolla, CA, USA) was used for data analysis between experimental cohorts. Two-tailed 
Student’s t-test and one-way ANOVA were performed. Significant differences were 
considered at P < 0.05. 
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Genetic knock-in with homology-directed repair 
Given the relatively high efficiency of short HDR inserts, we tested whether we could 
apply nuclease-driven, HDR-mediated insertion into the porcine genome to drive locus-
specific transgene expression. By using a short 5’ homology sequence, exogenous 
insertion of promoter elements may be avoided; when coupled with antibiotic selection, 
this has the capacity to limit off-target insertion. Two gRNAs were constructed to excise 
the porcine thrombomudulin gene (NCBI ID: 100157642), one targeting the ATG 
translation start site and the other targeting the region immediately 5’ to the translation 
stop site (5’-CACCGAGGAGCAGAACGCGGAGCA-3’ and 5’-
CACCGGTCTGTGGCCCAGATGCCA-3’ respectively). A ‘landing pad’ for HDR-
transgene delivery was constructed with 50bp homology in the 5’ and 360bp in the 3’ 
region. In between these homology arms, promoterless transcripts for GFP and 
Puromycin were inserted using the 2A linker as described by Lee et al.[70]. Cells were 
transfected with 2.5µg of each nuclease vector and 2µg of landing pad.  48 hours after 
transfection, cells were selected with puromycin. Individual clones were picked and 
analyzed for locus-specific insertion by PCR, transgene expression of GFP fluorescence 
was detected by flow cymotery performed using an Accuri C6 flow cytometer (Accuri, 
Ann Arbor, MI, USA).   
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RESULTS  
	
Phenotype-specific mutation efficiency is increased with non-integrating selection 
Expression of a fluorescence protein on the Cas9 vector created a useful non-integrating 
selection marker. Expression of GFP was detectable at 24 hours post transfection but was 
silent at both 7 and 14 days post transfection. GFP positivity on the Cas-9-expressing 
vector allowed for selective exclusion of 97% of the transfected population. After 
population sorting and expansion in culture, this method was successful in increasing 
nuclease-delivered mutation efficiency for both primary and immortalized porcine aortic 
endothelial cells (Figure 2.1A). Flow cytometric selection by this marker increased 
phenotype-silencing mutation rates from 3.5 to 82% in primary porcine aortic endothelial 
cells. Similar efficiency was achieved in an immortalized cell line.  
 
Genotypic mutation efficiency is increased with non-integrating selection 
Sixty-two clones were isolated from a population undergoing conventional CRISPR/cas9 
transfection and 68 clones were isolated from a population subjected to GFP selection by 
sorting after 24 hours for the top 3% brightest cells. Sanger sequencing indicated 7 
(11.29%) of the unselected clones and 65 (95.58%) of the GFP-sorted clones contained 
mutations in the targeted region (Figure 2.1B). 
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Figure 2.1: Non-integrating (NI) selection enhances nuclease mediated phenotypic 
and genotypic mutation efficiency. 
	
To test the ability of a plasmid-based selection marker to increase the efficacy of 
nuclease-mediated gene silencing in porcine cells, a plasmid expressing guide RNA, 
Cas9 and GFP was compared to a control plasmid expressing guide RNA and Cas9 alone.  
The column-based selection method described by Li et al.[24] was also compared for 
reference. The Guide RNA was targeted to the GGTA1 porcine locus and gene 
expression was determined by flow cytometer 14 days after transfection (A). The 
genotypic frequency of insertion or deletion event delivered by these two plasmids was 
also queried at a second porcine locus, revealing that the non-integrating selection marker 
facilitated a genotypic mutation event with 96% efficiency (B).   Histograms are 
representative of all experiments preformed in triplicate.  
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HDR-directed genome editing 
Exogenous template-mediated HDR offers the ability to precisely control gene 
modifications to enable a new level of specificity in the modification of genomic 
sequences for experimental and therapeutic application.  In the context of improved 
nuclease-directed mutation efficiencies, we queried whether we could use exogenous 
DNA oligonucleotides (Figure 2.2A) to facilitate nuclease-mediated HDR in porcine 
aortic endothelial cells.  We found that relatively short template sequences, when 
introduced at the time of nuclease-delivery, could effect HDR-mediated editing with 
remarkable efficiency. HDR-mediated template insertion was achieved at a rate of 11-
38%, with a biallelic insertion rate of 6-22% as verified by restriction digest and Sanger 
sequence (Figure 2.2C-D).  
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Figure 2.2: Design and use of exogenous DNA oligomers in nuclease-mediated 
genome editing. 
	
Short exogenous DNA oligonucleotides were designed with homology to a CRISPR-
targeted cut site at the GGTA1 translation start site within the porcine genome. All 
oligomers were designed to replace the GGTA1 start codon with the EcoRI restriction 
enzyme sequence (A). These oligomers were co-transfected at the time of nuclease 
delivery and were present during the creation of targeted DNA damage (B). To determine 
the insertion of exogenous template sequences by homology-directed repair, genomic 
DNA from clonal populations was amplified at the GGTA1 locus and then subjected to 
restriction enzyme digest and Sanger sequence (C-D). 
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As shown in figure 2.3, ssDNA was more effective at inducing mutation than 
dsDNA.  In addition, the presence of short exogenous template sequences increased the 
aggregate mutational event rate, defined as the sum of phenotype-altering mutation 
effected by NHEJ and HDR. As can be seen by phenotypic analysis, the presence of short 
exogenous sequences for HDR, increased the frequency of biallelic mutational events; in 
the absence of template mediated mutation, a sanger-verified heterozygote population 
remains weakly positive by flow cymotery (Figure 2.3 Control). 
 
 
 
 
 
 
 
 
 
 
	36 
 
Figure 2.3: Homology-directed repair by short exogenous oligomers facilitates 
increased gene silencing.  
	
To test the ability of short exogenous DNA sequences to direct homology-mediated 
repair of nuclease-induced genome cleavage, oligomers were designed with homology to 
a nuclease cut site within the porcine genome. Exogenous oligomers ranged in size from 
30bp to 50bps and were either single or double stranded. They were delivered in 
concentration of 1uM or 5uM at the time of nuclease transfection, gene expression was 
determined by flow cytometer after 14 days. A control group received no exogenous 
oligomer. Double stranded oligomers (DS DNA) were less likely to promote phenotype-
silencing mutation than single stranded oligomers (SS DNA). Furthermore, the template 
strands complimentary to the strand recognized by the CRISPR guide RNA, appeared to 
have the best efficiency. Histograms are representative of all experiments preformed in 
triplicate.  
 
Genetic knock-in with homology-directed repair 
Due to the successful integration of very short DNA templates, we designed a 50bp 5’ 
homology arm for locus-specific transgene delivery to the porcine genome.  This leading 
homology strand for HDR-mediated transgene insertion was devoid of promoter elements 
	37 
and positioned at the porcine thrombomodulin gene translation start site. 48 hours after 
cotransfection with nuclease and exogenous transgenes, 15 individual clones were 
isolated from puromycin selection. The 50bp 5’ homology arm successfully directed 
transgene insertion to the porcine thrombomodulin loci in 15/15 (100%) of the selected 
clones. (Figure 2.4A) In all fifteen of these colonies, the endogenous thrombomodulin 
promoter facilitated expression of the two inserted exogenous genes (Figure 2.4B). 
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Figure 2.4: Locus-specific transgene delivery to the porcine genome facilitated by 
nuclease-targeted homology driven insertion. 
	
 Given the observed efficiency of short homology directed repair (HDR) templates, we 
tested whether nuclease-mediated insertion by HDR could drive locus-specific transgene 
expression in the porcine genome. Two promotorless exogenous genes –puromycin 
resistance gene and GFP- were placed 3’ to a very short homology sequence which was 
designed 5’ to a nuclease cut site. The cut site targeted the porcine thrombomodulin 
translation start codon, and the exogenous homology sequence contained no promoter 
elements. After contrasfection with nuclease and transgenic DNA, site-specific insertion 
was queried by PCR utilizing a forward primer 5’ to the homology sequence region and a 
reverse primer within the transgene. After selection by puromycon 15/15 (100%) of 
clones exhibited locus-specific insertion (A). Phenotypic expression of GFP was 
analyzed by flow cytometer; all colonies exhibited GFP expression by the endogenous 
porcine thrombomodulin promoter (B).  
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DISCUSSION  
 
Though various nuclease-based approaches have been employed to silence genes within 
the porcine genome, CRISPR/Cas9 offers several advantages over previous techniques; 
making it the best choice for optimization efforts. Chief among these advantages is the 
ease of its programmability. CRISPR utilizes a relatively flexible targeting system. 
Relying on short RNA signals to guide the nuclease, CRISPR is capable of recognizing -
and editing- any loci that contains a GN19NGG sequence where N refers to any 
nucleotide. Although even the length of guide target has recently proven flexible, the 
genomic target sequence for editing must have the NGG on its 3’ end. This sequence is 
termed the protospacer adjacent motif (PAM). In bacteria –where CRISPR exists as an 
adaptive agent of defense against viral DNA- the PAM is present in the DNA to be 
degraded but not on the RNA that will target it. For CRISPR to work in bacteria, both a 
targeting RNA sequence and a nuclease-recruiting RNA sequence must hybridize. By 
artificially creating a chimera of these two entities, a fully functional targeting system can 
be created for use across many genomes; this structure is termed the single-guide RNA 
(sgRNA). For genome-editing purposes, functional sgRNA may be synthesized 
exogenously or they may be transcribed from an inserted plasmid. Once inside the cell, 
they serve as a mobile guide, capable of directing targeted genomic modification. The 
independent mobility of both sgRNA and Cas9 offers another advantage to the 
CRISPR/Cas9 system. Because sgRNA are independent of the Cas9 nuclease, which is 
free to associate and dissociate with multiple sgRNAs, CRISPR may be multiplexed. 
Multiplexing CRISPR has made it possible to effect many genetic modifications within a 
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single transfection. In 2015 Li et al described the use of multiplexed CRISPR technology 
to target multiple genes within a single reaction and produce pigs of multiple different 
genetic backgrounds within in a single pregnancy.   
Multiplexed or not, the essential common component of CRISPR editing 
strategies involves creating a targeted double strand break (DSB) in the genome. This is 
done by a cleavage domain of the Cas9 endonuclease. As shown in figure 2.5, Cas9-
induced DSBs are repaired by one of two mechanisms: nonhomologus end-joining 
(NHEJ) or homology directed repair (HDR). NHEJ is a well-characterized endogenous 
DNA repair pathway that is responsible for repairing insults to the host genome. NHEJ 
relies on DNA ligase IV to repair DSBs; because the fidelity of this enzyme is relatively 
low, NHEJ is said to be ‘error-prone.’ NHEJ often results in the presence of insertion or 
deletion mutations within repaired DNA. In this way CRISPR-directed DSBs provide an 
efficient means of silencing a gene, simply by disrupting the translational reading frame.  
An alternative approach to repairing CRISPR-induced DSBs involves the process of 
HDR. HDR requires the insertion of exogenous DNA templates that have homology to 
the CRISPR target. We show within this report that exogenous ‘donor template’ 
sequences are capable of inserting themselves into the porcine genome by relying on host 
genome repair mechanisms. In this way HDR-mediated DNA repair can be utilized as a 
means to introduce specific mutations or to insert exogenous sequences into the targeted 
loci. 
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Figure 2.5: Nuclease-based genetic insertion strategy. 
	
CRISPR-induced double-strand breaks in genomic DNA may be repaired through one of 
two processes. The first involves the error-prone process of NHEJ. Owed to its relative 
low fidelity, frame-shifting point mutations may be introduced that create a null 
phenotype at that locus (figure left). Alternatively, HDR requires the presence of a 
homologous donor DNA template (figure right). In this process, simple homologous 
recombination occurs to repair the double-strand break; a highly homologous template 
may harbor salient exogenous (mutagenic) template, thereby introducing a controlled 
mutation or transgene.  
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The advent of the CRISPR/Cas9 system has dramatically increased the 
accessibility of nuclease-based genome editing. Applying these tools to the porcine 
genome also offers potential therapeutic application; genetically modified pigs –as 
surrogate organ donors- are increasingly becoming recognized as a potential solution to 
the growing shortage of transplantable organs.[15, 21, 71-73] However, for the potential 
of nuclease-based tools to be fully realized, cost-effective and efficient methods of 
improving cas9-mediated editing must be pursued. Although multiple efforts are 
underway to increase nuclease-efficiency,[74-76] plasmid-delivery of cas9 and single-
guide RNAs typically offer a 1-10% mutational efficiency. [69, 77, 78] 
This study represents the first efforts to specifically query Cas9 efficiency within 
the porcine genome. The results suggest that the use of a transiently expressed selectable 
marker on the nuclease-delivery plasmid enables enrichment of mutated cells. Similarly, 
by introducing targeted restriction enzyme sites into our mutational event, we show that 
restriction digest of clonal cell populations can reliably identify genomic modification. 
Given the high insertion efficiencies reported here, this strategy offers the ability to 
significantly reduce the time and cost required to create -and identify- modified cells.  
Recently Schumann et al. have reported similar increases in mutational efficiency 
by directly transfecting Cas9 protein and pre-prepared ribnucleoprotein guides at a 20uM 
concentration. [75] Although this strategy warrants great attention, we offer comparable 
results in the present study with a plasmid-based platform; this avoids the need to isolate 
ribonucleotide proteins and Cas9 exogenously. 
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Xenotransplantation of genetically modified porcine organs is increasingly close 
to clinical application. In the context of human trials, the mechanisms of genome editing 
must move beyond efficiency to also incorporate great precision. The inclusion of very 
short oligonucleotide templates by nuclease-directed HDR offers this precision. 
Specifically, controlling the mutational event by short exogenous templates offers an 
avenue to achieve biallelic homozgosity (Figure 2.5). By accepting only mutations that 
possess mutations with allelic homozygosity, we may limit the possibility of downstream 
chromosomal allele recovery by crossing over as described first by Orr-Weaver and 
Szostak.[79] One potential strategy to further increase the rate at which we achieve this 
precision could be to inhibit NHEJ during the mutation period. Although not applied 
within the present study, recent use of pharmacologic agents that inhibit mammalian 
NHEJ has demonstrated increases in HDR-mediated repair pathways, [76, 80] making 
this strategy a potential companion technique for the present work.  
Finally, nuclease-mediated HDR with exogenous DNA can move beyond 
enhancing the frequency and control of mutational events. It is reasonable to apply this 
technique to create meaningful codon substitutions, replace or remove whole exons, and 
as shown within this report, insert entire transgenes. Although it remains uncertain which 
-if any- human transgenes will be necessary to promote porcine-to-human 
xenotransplantation, the ability to place transgenes precisely into the porcine genome is a 
great advantage.   
Taken together, our results suggest that nuclease-driven genome editing can be 
enhanced by a non-integrating selection strategy. The introduction of short exogenous 
DNA sequences both offers control over the mutational event and aids genotype 
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selection. Furthermore, the use of a very short homologous sequence is able to guide 
precision transgene insertion to the porcine genome. This process has the potential to 
limit off-target insertion and facilitates transgene expression by an endogenous promoter. 
These studies collectively represent a cost-effective repertoire for enhancing the 
application of CRISPR/cas9 system within the porcine genome.   Their application will 
aid broadening applications for nuclease technology in the understanding and treatment 
of surgical disease.  
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CHAPTER THREE: Silencing the porcine iGb3s gene does not affect Galα3Gal 
levels or measures of anticipated pig-to-human and pig-to primate acute rejection. 
INTRODUCTION  
 
With the enhanced efficiency of porcine genome engineering as described in the previous 
chapters, attention was turned to utilizing these processes to create and analyze new 
animal models of xenotransplantation. Theoretically, enzymes that affect glycosylation 
patterns may alter cross-species immunogenicity of the transcriptome on an organismal 
level through post-translational glycosylation. As such, initial priority was given to the 
porcine glycome, rather than the proteome.  Galα1,3Gal (αGal) is a disaccharide 
synthesized in pigs but not in humans and old world monkeys. [81] (Figure 3.1A) 
Primarily, α-GAL is formed by the catalytic activity of the enzyme α-galactotransferase 
(GGTA1) by which galactose is added to Gal1–4GlcNAc structures present on 
glycoproteins or glycosphingolipids. [82]  (Figure 3.1C) In humans the GGTA1 gene is 
inactive and humans develop antibodies when exposed to a-GAL epitopes.[83] 
Following xenotransplantation, α-GAL antibodies promote hyperacute rejection (HAR). 
[84] To address the issue of a-Gal epitopes, GGTA1 null animals have been generated in 
order to eliminate the α-GAL epitope and eliminate HAR. [19, 22, 32, 85-87] However, a 
residual amount of α-GAL epitope reactivity has been recognized in biallelic GGTA1 
knockout pig cells and implicated as a possible contributor to chronic rejection of 
GGTA1-/- organs seen in non-primate models of xenotransplantation. [88-90] One reason 
suggested for this is that the α-GAL epitope can be biosynthesized by other members of 
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the galactotransferase enzyme family. (Figure 3.1C) In particular the enzyme 
isoglobotrihexosylceramide synthase (iGb3S) is known to generate the galα1,3gal 
disaccharides epitopes on glycosphingolipids by the addition of galactose to lactosyl 
ceramide. (Figure 3.1B) In a similar manner to GGTA1, the human genome includes 
iGb3s (NM001080438) and the gene is thought to be silent due to several mutations that 
prevent the formation of iGb3. [91].  
  
	47 
 
Figure 3.1: Illustration of alpha Gal and iGb3 
	
A Illustration of a-Gal. B Illustration of iGb3. C Comparison of a1,3 Gal transferase and 
iGb3 synthase. D Illustration of iGb3 biosynthetic pathway. [92] 
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Studies in other animals demonstrate that iGb3 levels are species specific. In rat 
thymus, iGb3 levels are moderate whereas in mouse and human thymus iGb3 is 
undetectable. [93] Moreover, iGb3 is tissue specific. iGb3 is not detectable in brain, liver, 
kidney, spleen, thymus, testis, lung, stomach, intestine, eye, spinal cord, and plasma of  
mice but is detected in murine dorsal root ganglia (DRG). [93] Further studies 
demonstrate that in mice iGb3 is an immune modulatory glycosphingolipid, whereby 
iGb3 binds to CD1d and is presented to the T-cell receptor (TCR) of invariant natural 
killer T (iNKT) cells. [94, 95] In addition, iGb3-primed bone marrow-derived dendritic 
cells exert a significant iNKT cell-mediated anti-tumor activity. [96] Consequently, both 
tissue- and species-specific differences in iGb3 levels make information gained from 
rodent models difficult to translate into the porcine-human or porcine-primate 
xenotransplant models. [93] 
This translation is made more difficult because iGb3s gene expression does not 
match iGb3 epitope levels.  In mice, iGb3s gene expression is ubiquitous within mouse 
tissues but iGb3 is detected only in the DRG. This disparity is potentially due to 
translational regulation or because of continuous flux in glycosphingolipid pathways. In 
particular iGb3 is a substrate for iGb4 synthase which converts iGb3 to iGb4. iGb4 does 
not contain the terminal Galα(1,3)gal epitope.  
Consequently, there is a conflict regarding the importance of iGb3/iGb3s in the 
literature. [91, 97] Within the context of pig-to-primate xenotransplantation, some argue 
for the importance of iGb3 while others have failed to detect iGb3 in porcine tissues. [98, 
99] To address this we have generated iGb3s gene (A3GalT2) knockout pigs in a 
GGTA1-/- background and compared α-GAL epitope expression, antibody binding 
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profiles, and antibody-mediated complement depended cytotoxicity between GGTA1-/- 
and GGTA1-/-/A3GalT2-/- double knockout pigs.   
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MATERIALS AND METHODS 
	
Knockout constructs 
Bicistronic CRISPR sgRNA expression vectors co-expressing the Cas9 gene were 
designed as described by Li et al. [67] to bind and cleave the GGTA1 gene beginning at 
position 293654066 of NC_010443.4 (forward: 
CACCGCGAAAATAATGAATGTCAA) and A3GalT2 gene beginning at position 
83572809 of NCBI reference NC_010448.3 (forward: 
CACCGCGCTGGCAGGACGTGTCCA).  Porcine liver-derived cells were cultured as 
previously described [38] and co-transfected with both of the above CRISPR vectors 
using the Neon transfection system (Life Technologies, Grand Island NY, USA) 
according to the manufacturer’s instruction.  
 
Selection and Genotyping  
CRISPR-transfected cells were subjected to a-Gal counter-selection process, as described 
by Li et al., [67] to enrich for a mutation-positive population. Genomic DNA from 
counter-selected cells and the derivative clonal animals was obtained by GeneElute 
Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich, St. Louis, MO, USA). PCR 
amplification of targeted-genes was performed using primers and conditions previously 
described. [67]  
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Somatic cell nuclear transfer (SCNT) 
All the animals used in this study were approved by the Institutional Biosafety and 
Institutional Animal Care and Use Committee of IUPUI.  SCNT was performed as 
described by Estrada et al., [100] using in vitro matured oocytes (DeSoto Biosciences Inc, 
St. Seymour, TN.). Cumulus cells were removed from the oocytes by pipetting in 0.1% 
hyaluronidase.  Only oocytes with normal morphology and a visible polar body were 
selected for SCNT. Oocytes were incubated in manipulation media (Ca-free NCSU-23 
with 5% FBS) containing 5 µg/mL bisbenzimide and 7.5 µg/mL cytochalasin B for 15 
min. Oocytes were enucleated by removing the first polar body plus metaphase II plate, 
and one cell was injected into each enucleated oocyte. Couples were fused and activated 
simultaneously by two DC pulses of 180 V for 50 µsec (BTX cell electroporator, Harvard 
Apparatus, Hollison, MA, USA) in 280mM Mannitol, 0. 1mM CaCl2, and 0.05mM 
MgCl2. Activated embryos were placed back in NCSU-23 medium with 0.4% bovine 
serum albumin (BSA) and cultured at 38.5 °C, 5% CO2 in a humidified atmosphere for 
about one hour, before being transferred into the recipient. Recipients were synchronized 
occidental gilts on their first day of estrus. 
 
A3GalT2 locus silence verification    
The genome of iGb3S knockout animals was analyzed at the A3GalT2 locus by sanger 
sequence to confirm the presence of biallelic gene-silencing events. Because the dorsal 
root ganglion (DRG) has been shown to exhibit the highest levels of iGb3S expression, 
porcine dorsal root ganglion isogloboside-3-synthase levels were determined in control 
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and knockout pigs using a commercially available ELISA kit as per manufacturer’s 
instructions (#MBS7205937, www.MyBiosource.com).  
 
αGal Phenotype analysis  
Pig tissue and cells were collected in accordance with Institutional Review Board and 
Institutional Animal Care and Use Committee approved protocols. GGTA1-null and 
A3GalT2/GGTA1-null and WT PBMCs, Lymph node cells (LNC) and Splenocytes were 
isolated from mature animals after euthanasia. Cells were stained with isolectin GS-IB4 
Alexa Fluor 488 conjugate (Life technologies, Carlsbad, CA USA) to examine the 
presence of the αGal epitope. Unlabeled cells were used as a negative control and WT 
cells served as positive control. Fluorescence detection was performed using an Accuri 
C6 flow cytometer (Accuri, Ann Arbor, MI, USA). Analysis of the median was 
performed with FlowJo version 8.8.7 (Treestar Inc., Ashland, OR). Results were reported 
in median fluorescence intensity (MFI).  
 
Tissue staining and confocal microscopy 
Tissues were procured from mature A3GalT2/GGTA1-null and GGTA1-null pigs after 
euthanasia.  Frozen sections of kidney were prepared. Mounted tissues were blocked in 
Odyssey blocking buffer (Li-Cor Biosciences, Lincoln, NE USA) in HBSS for 1 hour.  
The slides were then fixed in paraformaldehyde for 10 minutes.  Tissues were stained 
with isolectin GS-IB4 Alexa Flour 488 conjugate (Life technologies, Carlsbad, CA USA) 
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to visualize the presence of α-Gal [19]. Tissues were also stained with goat anti-Pig 
CD31 1:100 (R and D systems, Minneapolis, MN) to visualize the endothelial surface 
[101], followed by three PBS washes and bovine anti-goat IgG DyLight 649 (Jackson 
Immuno Research Laboratories Inc., West Grove, PA). Tissues were incubated for 1 hour 
at 4oC and washed three times with 0.1% HBSS Tween DAPI (Invitrogen, Carlsbad, CA) 
was added to all slides for 1 minute as a nuclear stain [75] followed by two 0.1% HBSS 
tween washes.  Tissues were mounted in ProLong Gold (Invitrogen, Carlsbad, CA). 
Confocal microscopy was accomplished using an Olympus FV1000 (Olympus America 
Inc., Center Valley PA, USA).  All confocal settings were set to isotype control levels.  
Tissue staining of PBMC for confocal analysis was also performed as above. 
 
Antibody binding 
GGTA1-null and A3GalT2/GGTA1-null PBMCs were isolated and assessed for viability 
using trypan blue. Approximately 200,000 PBMCs of each group were incubated with 
25% heat inactivated human sera from 10 healthy human and baboon donors for 1 hour at 
4oC.  Samples were then washed three times with HBSS. Human IgG and IgM were 
detected individually with anti-human secondary antibodies conjugated to Alexa Fluor 
488 (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) for 1 hour at 4oC. 
PBMCs were washed three times in HBSS. Fluorescence detection was performed using 
an Accuri C6 flow cytometer (Accuri, Ann Arbor, MI, USA). Analysis of the median was 
performed with FlowJo version 8.8.7 (Treestar Inc., Ashland, OR), and results were 
reported in median fluorescence intensity. 
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Complement-mediated cytotoxicity 
The assay was performed as described by Diaz et al. [102] with slight modifications. In a 
96-well V-bottom assay plate, 100 µl of serially diluted, heat inactivated human or 
baboon serum was mixed with a 100 µl aliquot of PBMC from either a GGTA1-null pig 
or A3GalT2/GGTA1-null pig. The final concentration of PBMC in each well was 
1x10^6/ml and serum concentration varied by dilution (50%, 17%, 6%, 2%, 0.6%, 0.2% 
and .07%). The assay was incubated for 30 mins at 4oC. After incubation, plates were 
centrifuged for 6 min (400x g), decanted and washed with HBSS; this step was repeated 
twice. Baby Rabbit complement (Cedarlane, Burlington, NC, USA) was diluted 1:15 in 
HBSS and 140 µl was added to each well and incubated for 30 mins at 37oC. PBMCs 
were labeled with a fluorescein diacetate (FDA) 1 µg/ml in acetone and propidium iodide 
(PI) prepared at a concentration of 50 µl/ml in phosphate-buffered saline (PBS). After 
incubation in complement, the samples were transferred from 96 well to flow tubes 
containing 100 µl HBSS and 10 µl FDA/PI. Analysis was completed by flow Cytometry. 
The percentage of dead cells (PI+, FDA-), damaged cells (PI+, FDA+) and live cells (PI-, 
FDA+) was determined by quadrant analysis. PI-/FDA- events were excluded from 
analysis. Background spontaneous cytotoxicity was determined by analyzing cells not 
exposed to human sera. Values for cytotoxicity are subsequently reported after correction 
by this background value using the following equation: %cytotox = (%cytotoxExp - % 
cytotoxSpont)/ (100 -%cytotoxSpont) where %CTXexp is the percentage of dead cells 
under the experimental condition. 
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Glycosphingolipid analysis. 
Sample Collection: GGTA1-/- animals are known to exhibit reduced levels of α-series 
glycosphingolipids which facilitates more resolute detection of iGb3 by HPLC. For this 
reason, porcine kidney samples were collected from GGTA1-/- A3GalT2-/- double knock 
out (DKO) and wild type pigs at Indiana University Medical School, USA under IACUC 
approved protocol. [47, 67] Samples were flash frozen in liquid nitrogen and stored at -
80oC prior to shipping under dry ice to DP at University of Oxford Department of 
Pharmacology, UK. Glycosphingolipid Extraction: Glycosphingolipids were extracted 
by chloroform/methanol extraction as per Svennerholm and Fredman [101] and solid 
phase purification (SepPac C18) as previously described. [103] Ceramide glycanase 
digestion: Extracted and purified glycoshingolipids were digested to release 
carbohydrates, using 50 mU ceramide glycanase at 37 °C for 18 hours as previously 
described. [104] Carbohydrate labeling: The ceramide-glycanase-released 
oligosaccharides were labeled with anthranilic acid, as previously described.  [103] 
Normal Phase HPLC: Anthranilic acid labeled oligosaccharides were separated by 
normal phase high performance liquid chromatography and detected by fluorescence, as 
previously described. [103] 
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RESULTS 
	
Gene knockout pigs 
Porcine, liver-derived cells transfected with the bisistronic sgRNA/Cas9 knockout vectors 
for GGTA1 and A3GalT2 genes exhibited biallelic gene-silencing mutational events; IB4 
lectin-conjugated beads facilitated the isolation of successfully mutated cells.  These cells 
were used to create healthy clonal animals by SCNT. The genotype of animals used in 
this analysis exhibited an A3GalT2/GGTA1-null or a GGTA1-null background and have 
been previously published by Li et al.[67] Sanger sequencing of genomic DNA obtained 
from knockout animals used within this study confirmed biallelic frame-shift mutational 
events, indicating gene silencing at the iGB3s locus. (Figure 3.2A) As show in figure 
3.2B, iGb3 synthase expression was silenced; dorsal root ganglion iGb3s production was 
reduced from 1.7±0.4ng/mg protein in WT pigs to 0.14±0.08 ng/mg protein in A3GalT2-/- 
pigs (p= 0.005); mutation within the A3GalT2 locus rendered iGb3s levels that were not 
statistically greater then the background zero standard (p=0.18). 
 
  
	57 
 
 
Figure 3.2: Nuclease-driven silencing of the isoglobotrihexosylceramide 3 synthase 
production in porcine tissue and cells.  
	
Tissue and cells isolated from WT and A3GalT2-null animals were immediately frozen 
for DNA and protein analysis. A Sanger sequence analysis of A3GalT2-/- animal 
genomic DNA that documents frame-shift gene silencing events in a biallelic pattern. B 
The results of a commercially available ELISA analysis documents successful disruption 
of iGb3s production in KO animals; iGb3S detection was significantly reduced (p=0.005) 
to levels of background absorbance in A3GalT2-/- animals; iGb3s levels in A3GalT2-/- 
pigs were not statistically greater than the background zero standard (p=0.18).  
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a-Gal phenotype analysis 
 Galα3Gal epitope expression, measured by IB4 binding, was not significantly different 
on cells or tissue from A3GalT2/GGTA1-null or a GGTA1-null animals. At the cellular 
level this was true for spleen cells, lymph node cells and PBMCs; histograms for IB4-
stained cells from A3GalT2/GGTA1-null and GGTA1-null animals overlay the 
corresponding unstained controls (Figure 3.3).  
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Figure 3.3:  Ib4 binding profiles of iGb3s knockout pig cells. 
	
Spleen cells, Lymph node cells and PBMCs, from wild-type (WT), GGTA1-null (GTKO) 
or A3GalT2/GGTA1-null (iGb3) animals were incubated with a fluorescent-conjugated 
IB4 lectin probe to detect αGal carbohydrate profiles. For each frame, blue represents 
A3GalT2/GGTA1-null cells, red represents GGTA1-null cells and grey is a WT positive 
control. IB4 binding was not significantly affected by silencing the iGb3s gene. A 
represents IB4 binding profiles of spleen cells B represents IB4 binding profiles of 
lymph-node cells C represents IB4 binding profiles of PBMCs.  In all panels, knockout 
animal histograms overlay unstained negative controls.  
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Tissue staining and confocal microscopy  
Confocal microscopy analysis showed no visible changes to IB4 binding at the tissue 
level between A3GalT2/GGTA1-null and GGTA1-null kidneys (Figure 3.4).   
 
 
Figure 3.4: Confocal analysis of IB4 binding to iGb3s knockout pig tissues.   
	
Sections of kidney tissue were obtained from mature WT, GGTA1-null or 
A3GalT2/GGTA1-null pigs after euthanasia. These tissues were stained with IB4 lectin 
[19] to show Galα3Gal expression level, anti-CD31 [101] endothelial marker and a DAPI 
[75] nuclear stain.  
 
Antibody binding  
IgG and IgM antibody binding from baboon sera and human sera was unchanged 
between PBMCs from A3GalT2/GGTA1-null and GGTA1-null animals (Figure 3.5).   
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Figure 3.5: Baboon and human antibody binding profiles of iGb3s knockout pig 
cells. 
	
Baboon and human sera were incubated with PBMCs from swine containing inactivated 
GGTA1, or GGTA1 and A3GalT2 genes. Secondary fluorescent antibodies were used to 
detect IgG and IgM binding to the cells with median fluorescence intensity being 
evaluated (MFI). T-test statistical analysis was used to analyze the difference between 
genotype cohorts; baboon and human IgG and IgM binding was not statistically affected 
by silencing the iGb3s gene. For each frame, blue represents A3GalT2/GGTA1-null cells, 
red represents GGTA1-null cells and grey is an isotype control. A represents patterns of 
IgG and IgM binding to baboon sera. A representative histogram (above) is paired with 
an aggregate plot of all 10 sera analyzed (below).  The diagonal line indicates equivalent 
binding to both single and double knockout cells. B represents patterns of IgG and IgM 
binding to human sera. A representative histogram (above) is paired with an aggregate 
plot of all 10 sera analyzed (below).  The diagonal line indicates equivalent binding to 
both single and double knockout cells.  
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Antibody-dependent complement-mediated cytotoxicity 
Similarly, antibody-mediated complement-dependent cytotoxicity, was not reduced by 
the silencing of the iGb3s gene (Figure 3.6). The lysis profiles of PBMCs from 
A3GalT2/GGTA1-null and GGTA1-null animals were equivalent when subjected to 
baboon sera and human sera.  
  
	63 
 
Figure 3.6: Antibody-mediated complement-dependent cytotoxicity of baboon and 
human sera against GGTA1-null or A3GalT2/GGTA1-null cells.  
 
PBMCs were isolated from GGTA1-null or A3GalT2/GGTA1-null pigs. These were 
subjected to heat-inactivated baboon and human sera as a source of antibody.  
Complement-mediated cell-lysis was induced by the addition of rabbit complement and 
measured in a live/dead dual-labeling assay. Example curves for antibody-mediated 
complement-dependent cytotoxicity against GGTA1-null [101] or A3GalT2/GGTA1-null 
cells [75], are above aggregate median dilutional cytotoxicity at which point sera effected 
50% cell death. T-test statistical analysis was used to analyze the differences between 
genetic cohorts; complement-mediated lysis was not statistically affected by silencing the 
iGb3s gene. A represents baboon sera toxicity B represents human sera toxicity.  
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Glycosphingolipid Analysis  
Although silencing the porcine iGb3s gene did not affect patterns of IB4-binding, 
antibody binding, or antibody-mediated cytotoxicity, the glycosphingolipid profile of 
these animals was altered. HPLC analysis of tissue obtained from GGTA1-/-A3GalT2-/- 
animals evidenced a unique glycosphingolipid profile compared to the wild type animals. 
In particular, iGb3 was not detected in renal tissue from wild type or DKO pigs. iGb3 
elutes between Gb3 and GM3 and no appropriate peak was observed. (Figure 3.7A,B) 
Detection of iGb3 is difficult because of the abundance of Gb3 and GM3 in wild type 
pigs, which limits resolution between peaks. This is particularly challenging when GM3 
is high as seen in wild type pigs (Figure 3.7A). In DKO pigs there was a significant 
reduction in α-series glycosphingolipids that include GM3 which makes detection of 
iGb3 easier. This reduction in GM3 is probably related to the GGTA1 gene deletion 
rather than deletion of A3GalT2. A similar loss of GM3 is reported in α-gal null mouse 
tissues. [93] Despite the reduction of GM3 detection of iGb3 was not detectable. Gb3 
levels were slightly increased in DKO pigs which hindered iGb3 detection. Typically 
iGb3 can be detected at 1% of Gb3 levels in the absence of GM3. Because both Gb3 and 
GM3 were present in DKO pig kidney detection of iGb3 is significantly challenging. Our 
failure to detect iGb3 in wild type porcine kidneys is in accordance with previous studies 
of iGb3 in pigs, using linear ion-trap mass spectrometry detection, that was unable to 
detect iGb3 in pig heart, liver, kidney and pancreas. [97] In contrast to iGb3 
quantification we did observe a potential reduction in the levels of iGb4 in kidneys from 
DKO pigs, when compared to wild type controls. iGb3 is converted to iGb4 by the 
enzyme iGb4 synthase. iGb4 elutes between GM2 and Gb4. (Figure 3.7B) Moreover, 
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iGb4 was potentially identified, suggesting a rapid conversion of iGb3 to iGb4, which 
would explain the absence of iGb3 in wild type pig kidneys. In kidneys from DKO pigs 
iGb4 was not detected. Because iGb4 peaks are unaffected by GGTA1 silencing -as the 
synthetic pathway is independent of Alpha-1,3-galactosyltransferase and employs a 
unique precursor, the A3GalT2 locus is implicated in this observation. [93] This suggests 
the direct reduction of substrate iGb3 relating to iGb3 synthase gene deletion.  (Figure 
3.1D) [93] 
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Figure 3.7: Liquid chromatography analysis of kidney tissue from wild type and 
A3GalT2-null animals.   
	
A represents elution patterns from WT kidney sample and B represents elution patterns 
from A3GalT2-null sample. iGb4 elutes just before Gb4 in a WT, and the triplet peak in 
the WT pig becomes a doublet in the A3GalT2- null sample. This is indicative of 
upstream silencing of the iGb3s enzyme. Inversion of the ratio between GM2 and GB4 
further suggests substrate shunting towards GB4 production in the absence of functional 
iGb3s in A3GalT2-/- animals. 
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DISCUSSION  
 
As discussed within chapter one, the shortage of donor organs is the most pressing 
problem in clinical transplantation. [105] Xenotransplantation of pig organs is becoming 
an immunologically realistic solution to this problem. [47] However, to achieve clinical 
relevance, the major drivers of immune-mediated, antibody-mediated rejection (AMR), 
must be understood and eliminated. [106] Over the course of evolution, humans and 
primates have inactivated the α-1,3-glycosyltransferase-1 (GGTA1) gene and form 
antibodies to α-GAL epitopes within xenotransplanted porcine organs. The biallelic 
(GGTA1) knockout pig represented the first successful step towards ‘humanizing’ 
porcine organs for xenotransplant. Nevertheless, porcine-baboon xenotransplant studies 
using GGTA1-/- pig cells have demonstrated residual α-Gal antibody formation and 
chronic cytotoxicity, suggesting additional sources for α-Gal epitopes. An alternative 
cause for α-gal biosynthesis is the enzyme isoglobotrihexosylceramide synthase (iGb3s). 
Some groups have suggested that iGb3s may function to replace a residual amount of α-
GAL epitope in GGTA1-/- animals, whereas others argue against such a role. [91, 107] To 
address any ambiguity, this study directly investigated the role of iGb3 by creating and 
comparing GGTA1-/- pigs with GGTA1/A3GalT2-/- double KO pigs. Our results show 
that there is no meaningful contribution to α-GAL levels by iGb3s. Although there is a 
very small trend (Figure 3.2) towards lower α-GAL expression in the iGb3s-null animal 
cells, this difference was not appreciated at the tissue level (Figure 3.3) and both antibody 
binding and cytotoxicity remained unchanged by inactivating iGb3s (Figure 3.4). We are 
cognizant that IB4 binding to iGb3 is reduced when compared to α-GAL and so the 
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staining might not be a true reflection of iGb3 levels. [108] However, IB4 does bind to 
iGb3 and the purpose of this study was to determine comparative reductions in IB4 
binding associated with iGb3s silencing. Although the absolute levels of iGb3 are not 
reflective of IB4 staining, there was no significant reduction in staining associated with 
deletion of iGb3s gene.  
 A lack of measured role for iGb3s in acute rejection is not unexpected. Anti α-
Gal reactive antibodies are found in GGTA1 KO pigs and mice with no discernable acute 
or chronic reaction. [109-112] This is probably because anti α-Gal antibodies can 
differentiate between α-GAL carbohydrate epitopes associated with lacNAc (GGTA1) 
and LacCer (iGb3) core structures. [107] Most preformed antibodies recognize LacNAc 
form of α-GAL rather than the LacCer form, even though the terminal disaccharide is 
identical. Millard et al. do report an iGb3 specific antibody from GGTA1-/- mice that 
argues in favor of a role for iGb3s. [107] However, the specificities to antibodies 
produced by Milland et al. has been questioned because the over expression of iGb3s is 
likely to generate more than just iGb3 and will generate pol-GAL glycosphingolipids 
such as Galα1,3Galα1,3Galα1,3Galα1,3Galβ1,4Glcβ1,1Cer. [113] Moreover, translation 
of murine studies to porcine-human xenotransplantation is problematic. In particular 
GGTA1 gene null mice are known to have lower levels of natural anti α-Gal antibodies 
when compared to humans and old world primates. In the study by Malland et al. mice 
were immunized against α-Gal in order to generate antibodies. [107] Consequently, it is 
not unexpected that the mice would generate antibodies that recognized iGb3 like 
epitopes. In contrast, neither humans nor baboons were immunized against α-Gal, 
therefore antibody binding to porcine PBMC cells from GGTA1-/- and GGTA1-/-
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/A3GalT2-/- pigs was minimal. Consequently, immunological quantification of iGb3 is 
uncertain.  
 In order to better understand the role of iGb3 levels in hyper acute rejection we 
performed glycosphingolipid analysis by NP-HPLC of kidneys from wild type and DKO 
pigs in order to detect iGb3. In wild type pigs iGb3 was below detectable limits. This is 
in accordance with previous studies of iGb3 in pigs using linear ion-trap mass 
spectrometry detection, whereby IGb3 was undetectable in pig heart, liver, kidney and 
pancreas. [97] The absence of detectable iGb3 can be explained by a rapid conversion of 
iGb3 to IGb4 by IGb4 synthase. (Figure 3.1D) In wild type pigs IGb4 was potentially 
detected as a peak eluting between GM2 and Gb4. Confirmation that this peak accurately 
represents iGb4 requires digesting the sample with a specific hexosaminidase to convert 
iGb4 to iGb3. For this study digestion was not performed, because the focus is on 
potential sources of residual α-Gal epitope and iGb4 does not contain a terminal a-gal 
epitope. However, by monitoring renal glycosphingolipid profiles in A3GalT2 knock out 
pigs we did observe a general disruption of glycosphingolipid metabolism and no iGb4 
peak; suggesting that deletion of iGb3 synthase reduces the iGb3 substrate for IGb4 
synthase.   
In conclusion, our data suggests that iGb3s is not a contributor to AMR in pig-to-
primate or pig-to-human xenotransplantation. Although, iGb3s gene silencing 
significantly changed the renal glycosphingolipid profile, the effect on Galα3Gal levels, 
antibody binding, and cytotoxic profiles of baboon and human sera on porcine peripheral 
blood mononuclearcytes (PBMCs) was neutral. In contrast, recently created triple 
xenoantigen KO pigs have reduced xenoreactive antibody binding and suggest that 
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further work should continue to focus on genomic editing for the reduction of non-αGal 
xenoantigens and xenopeptides. [38, 47, 106, 114] 
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CHAPTER FOUR: Silencing porcine genes significantly reduces human-anti-pig 
cytotoxicity profiles: an alternative to direct complement regulation. 
INTRODUCTION  
	
Continuing my inquiry into the immunologic importance of the porcine glycome in pig-
to-human xenotransplantation, this chapter describes a comparison between two novel 
model animals for the study of pig-to-human xenotransplantaion. As described in the 
previous chapter, the unmodified porcine glycome has great potential to limit clinical 
application of solid xenotransplantation by effecting antibody-mediated rejection. 
Genetically modified porcine organs offers an answer to this problem.  Although 
strategies of genetic modification have ‘humanized’ the porcine model towards clinical 
relevance, acceptable levels of human anti-porcine cytotoxicity have not previously been 
described. Most notably, these approaches have aimed at either antigen reduction or 
human transgene expression. The object of this study was to evaluate the relative effects 
of both antigen reduction and direct complement regulation on the human-anti-porcine 
complement dependent cytotoxicity response. 
As aforementioned, the use of genetically modified porcine organs for clinical 
transplantation has not progressed to the clinic because of antibody-mediated rejection 
(AMR) that occurs shortly following graft reperfusion. AMR is mediated by the binding 
of xenoreactive antibodies to antigens on the porcine endothelial cell (EC) surface, 
followed by complement activation leading to EC injury. Two genetic engineering 
strategies in donor pigs have been employed to minimize the impact of xenoreactive 
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antibodies on xenograft survival.  The deletion of endothelial xenoantigens such as the 
Gal[alpha]1–3gal epitope (αGal) as well as the insertion of  human complement 
regulatory protein (hCRP) transgenes have been used in pigs to limit EC injury. [115]  
Human CD55, also known as decay accelerating factor, is the most widely utilized hCRP 
transgene. It acts downstream to antibody binding by limiting the ability of C3b to 
potentiate complement-mediated EC damage. It has previously been shown that when 
expressed in porcine cells, this transgene limits human and primate antibody mediated 
complement-dependent cytotoxicity. [116] As a strategy to limit antibody-mediated 
damage, these proteins have proven valuable within the relatively high antigen 
background of wild type or αGal-negative pigs.  Recently, the antigen barrier has been 
significantly reduced by the sequential identification and removal of two more 
xenoantigens produced by the CMAH and B4GalNT2 genes. [47]    
There are two main forms of sialic acid in mammals N-acetylneuraminic acid 
(Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc).  The CMAH gene is responsible for 
the creation of Neu5Gc.  This gene was deleted during the course of evolution in humans 
because it conferred a protective advantage against a prevailing malaria strain. [117]  The 
net result is that humans produce antibodies that react with Neu5Gc on the surface of pig 
cells.  Deletion of the GGTA1 and CMAH gene produced pigs whose cells had less 
human antibody binding than chimpanzee cells. [29]  
Byrne and McGregor used serum from primates that had rejected GGTA1-/- pig 
hearts to screen a cDNA library from GGTA1-/- pig endothelial cells to identify an 
enzyme, Beta-1,4-N-Acetyl- Galactosaminyl Transferase 2 (B4GALNT2), that produces 
a glycan to which humans and non-human primates have antibodies. [118, 119] Although 
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it is not yet clear which glycan is affected by the B4GALNT2 enzyme, deleting the 
porcine genes for B4GALNT2 in addition to GGTA1 and CMAH reduced human 
antibody binding to pig peripheral blood mononuclear cells (PBMCs), to the point where 
early antibody mediated rejection would not be expected. [47]        
In xenotransplantation like allotransplantation, the risk of antibody-mediated 
rejection can be assessed by crossmatch analysis.   A crossmatch involves placing 
recipient serum onto donor PBMCs.  In allotransplantation, only IgG and not IgM, is 
considered.  The reaction was initially a cellular cytotoxicity assay using fluorescent 
dyes, but has more recently been performed using flow cytometry to assess the degree of 
antibody binding. [120]  Flow cytometry readout is expressed as median fluorescence 
intensity (MFI), and generally MFI background (cells only) is around 2,000.  As 
described in Table 1, this value would represent a completely negative crossmatch.  
Crossmatches with MFIs between 2,000-5000, indicate donor specific antibody is present 
but at levels that are unlikely to create clinical issues. Crossmatches with MFIs between 
5,000-9,500 are acceptable for transplant, but sometimes necessitate treatment with either 
plasmapheresis or IVIG.  A flow crossmatch with elevated MFIs > 9,500 would result in 
a positive cellular dependent cytotoxicity crossmatch. At these levels, the risk of AMR 
prohibits clinical application even within the context of desensitization protocols.        
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Table 4.1: Interpretation of Flow Cytometric Crossmatch values for allograft 
allocation 
	
MFI* Clinical interpretation for allograft allocation 
≤ 2,000 Background fluorescence (negative crossmatch)  
2000-5,000 Acceptable for transplant without recipient desensitization 
5,000- 9,500 IVIG or Plasmapheresis recommended before transplant [121] 
> 9,500 Positive Crossmatch with high risk of early AMR** graft loss 
*MFI, median fluorescence intensity; **AMR, antibody-mediated rejection  
 
Human complement regulatory transgenes have proven ability to limit porcine 
endothelial cell damage in the presence of antibody binding. The purpose of this work 
was to examine the benefit of a hCRP transgene within a lower antigenic background 
than has previously been studied. Furthermore, we describe the first characterization of 
the effect of silencing the B4GalNT2 gene on human antibody-mediated cytotoxicity.  
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MATERIALS AND METHODS  
 
Construction of hCD55 Plasmid  
All restriction and modification enzymes used were purchased from Thermo Scientific 
(Vilnius, Lituania) unless otherwise stated. First step was the conversion of our plasmids 
to the Multisite GatewayÒ (MG) system (Life Technologies, Carlsband, CA). The 
pCXEGFP expression cassette was excised with  XmaCI+SalI digestion from the 
pMGEGFP5’3’MARHyg2272 and its resulting arms were blunted by T4 polimerase 
treatment in order to insert the blunted MG conversion cassette OrfA (Life 
Technologies). The resulting pMG5’3’MARHyg2272rev-OrfAPLrev destination vector 
presented 2 matrix attachment regions (MAR) of the chicken lysozyme [122] flanking the 
OrfA cassette on a pBlueScriptIIKS+ backbone (Stratagene, Cedar Creek, TX). The 
ubiquitous hybrid promoter of pCAGGS expression vector  was chosen for our 
experiments, obtaining the pCAGGS-hCD55 expression cassette. [123, 124] The hCD55 
Entry clone was obtained cloning pCAGGS-hCD55/PstI S1nuclease-treated+SalI 
fragment (3363 bp) into the Entry clone pENTRL1L2-OligoSacISalIuni (previously 
obtained in our laboratory) digested with SalI+SmaI restriction enzymes. After MunI 
recognition site deletion  by T4 polymerase treatment, the resulting pENTRL1L2-
CXhCD55delMunI Entry clone was finally exchanged with the 
pMG5’3’MARHyg2272rev-OrfAPLrev using the LR ClonaseÒ enzyme mix (Life 
Technologies). 
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Production of Genetically modified animals 
Genetically modified pigs were created utilizing a CRISPR/Cas9 approach and somatic 
cell nuclear transfer as previously described.[24] Briefly, bicistrionic CRISPR sgRNA 
expression vectors co-expressing the Cas9 gene were designed to target the GGTA1, 
CMAH and B4GalNT2 genes within the first exon. A human CD55-espressing cassette 
was designed for hCRP transgene introduction.  After transfection and selection, 
modified cells served as nuclear donors for somatic cell nuclear transfer (SCNT) to create 
clonal animals. Animals were grown to maturity and blood was obtained by peripheral 
venous sample. All the animals used in this study were approved by the Institutional 
Biosafety and Institutional Animal Care and Use Committee of IUPUI.   
 
Antibody binding 
Peripheral blood was obtained by venous sample from CMAH-/- GGTA1-/-,  hDAF+ 
CMAH-/- GGTA1-/- , and  CMAH-/- GGTA1-/- B4GalNT2-/- animals. Peripheral blood 
mononuclearcytes (PBMCs) were isolated by Ficoll-Paque centrifugation (GE Health, 
Uppsla, Sweeden) and assessed for viability using Trypan blue.  200,000 PBMCs of each 
group were incubated with 25% heat inactivated human sera from 10 healthy human 
donors for 1 hour at 4oC.  Samples were then washed three times with Hank’s Buffered 
Salt Solution (HBSS). Human IgG and IgM were detected individually with anti-human 
secondary antibodies conjugated to Alexa Fluor 488 (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA) for 1 hour at 4oC. PBMCs were washed three times 
in HBSS. Fluorescence detection was performed using an Accuri C6 flow cytometer 
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(Accuri, Ann Arbor, MI, USA). All experiments were preformed in triplicate. Analysis of 
the median was performed with FlowJo version 8.8.7 (Treestar Inc., Ashland, OR) n=10. 
 
Antibody-mediated complement-dependent cytotoxicity 
The assay was performed as described by Diaz et al. [102] with slight modifications. In a 
96-well V-bottom assay plate, 100 µl of serially diluted heat inactivated human serums 
from ten healthy volunteers ages 21-63 was mixed with a 100 µl aliquot of PBMC from 
either a CMAH-/- GGTA1-/-,  hDAF+ CMAH-/- GGTA1-/-  or CMAH-/- GGTA1-/- 
B4GalNT2-/- animal. Although lytic assays for allograft screening utilize a process to 
remove IgM antibodies from recipient sera, IgM was left intact within these assays to 
determine the highest potential killing. The final concentration of PBMC in each well 
was 1x10^6/ml and serum concentration varied by dilution (100%, 50%, 17%, 6%, 2%, 
0.6%, and 0.2%). The assay was incubated for 30 mins at 4oC. After incubation, plates 
were centrifuged for 6 min (400x g), decanted and washed with HBSS; this step was 
repeated twice. Heat inactivation of human sera prevents the variable presence of 
complement within stored sera from affecting results. Baby Rabbit complement, a 
common stable substitute for human complement, (Cedarlane, Burlington, NC, USA) was 
diluted 1:15 in HBSS and 140 µl was added to each well and incubated for 30 mins at 
37oC. PBMCs were labeled with a fluorescein diacetate (FDA) 1 µg/ml in acetone and 
propidium iodide (PI) prepared at a concentration of 50 µl/ml in phosphate-buffered 
saline (PBS). After incubation in complement, the samples were transferred from 96 well 
to flow tubes containing 100 µl HBSS and 10 µl FDA/PI. Analysis was completed by 
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flow Cytometry. The percentage of dead cells (PI+, FDA-), damaged cells (PI+, FDA+) 
and live cells (PI-, FDA+) was determined by quadrant analysis. PI-/FDA- events were 
excluded from analysis. Background spontaneous cytotoxicity was determined by 
analyzing cells not exposed to human sera. Values for cytotoxicity are subsequently 
reported after correction by this background value using the following equation: 
%cytotox = (%cytotoxExp - % cytotoxSpont)/ (100 -%cytotoxSpont) where %CTXexp is 
the percentage of dead cells under the experimental condition.  
 
Statistics 
Flow cytometric results were reported in mean fluorescence intensity (MFI) values for 
each human serum subjected to both test group PBMC for IgG and IgM assays. 
Antibody-mediated complement-dependent cytotoxicity data was plotted into a non-
linear regression model, by taking the log of each of the seven serum dilution against the 
corresponding percentage of cytotoxicity to estimate serum DC50. The comparison of 
cytotoxicity and antibody binding cohorts was performed using a two-tailed student’s t-
test. P-values < 0.05 were considered statistically significant. All experiments were 
performed in technical and biological triplicate.  
 
Tissue staining and confocal microscopy 
Tissue and PBMCs were procured from hDAF+ CMAH-/- GGTA1-/-  piglet after 
euthanasia.  Mounted samples were blocked in Odyssey blocking buffer (Li-Cor 
Biosciences, Lincoln, NE USA) in HBSS for 1 hour.  The slides were then fixed in 
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paraformaldahyde for 10 minutes.  Samples were stained with hCD55-phycoerythrin 
conjugate (Santa Cruz Biotechnology, Inc. Santa Cruz, CA) to visualize the presence of 
the hDAF.  Tissues were incubated for 1 hour at 4oC and washed three times with 0.1% 
HBSS. DAPI (Invitrogen, Carlsbad, CA) was added to all slides for 1 minute as a nuclear 
stain followed by two 0.1% HBSS washes.  Samples were mounted in ProLong Gold 
(Invitrogen, Carlsbad, CA).  Confocal microscopy was accomplished using an Olympus 
FV1000 (Olympus America Inc., Center Valley PA, USA).  All confocal settings were 
set to isotype control levels.   
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RESULTS  
 
Genetic modification of porcine cells and SCNT produced healthy pigs. Cells from 
CMAH-/- GGTA1-/- (DKO), hDAF+ CMAH-/- GGTA1-/-  (DKO CD55+), and CMAH-/- 
GGTA1-/- B4GalNT2-/- [125] animals exhibited the expected glycan-null phenotypes 
(Figure 4.1). The DKO CD55+ animals achieved hCRP transgene expression (Figure 
4.2). As expected, human IgG and IgM antibody binding levels were unchanged between 
the DKO and the DKO CD55+ animals. Human IgG and IgM antibody binding were 
significantly lower to the TKO animal. As displayed in figure 4.3, Median IgG and IgM 
MFI values for DKO cells were 3917.1 (SEM=1057.1) and 5615.2 (SEM= 1270.3) 
respectively. IgG and IgM values for TKO cells dropped to 1952.4  (SEM= 226.1) and 
3185.9 (SEM= 379.4) respectively. This represented a 49.1% (p= 0.012) reduction in IgG 
and 43.2% (p= 0.002) reduction in IgM binding when compared to the DKO background. 
The new reduction in antibody binding brings a pig-to-human crossmatch within ranges 
associated with matched allograft allocation. (Table 4.1) Compared to the DKO, human 
anti-porcine cytotoxicity was reduced by 8% with the addition of a hCRP (p=.046). As 
displayed in figure 4.4, it was reduced by 54.3% with silencing the B4GalNT2 gene 
(p=.0002). Reductions in cytotoxicity to the TKO animal varied between human sera. 
The magnitude of reduction to complement-mediated cytotoxicity was directly 
proportional to reductions in human IgM binding when compared across individual sera 
(Figure 4.5). 
 
	81 
 
Figure 4.1: Phenotypic silence of porcine carbohydrate genes. 
	
A: Confocal analysis of Porcine WT Liver tissue stained with DAPI and HD (above); 
flow cytometric analysis of PBMCs from Porcine WT PBMCs stained for Neu5Gc and 
Isotype control (Below). B: Confocal analysis of Porcine CMAH Liver tissue stained 
with DAPI and Anti-Neu5gc (above); flow cytometric analysis of PBMCs from Porcine 
WT PBMCs stained for Neu5Gc and Isotype control (below). 
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Figure 4.2: Transgenic expression of hCD55 on porcine tissue and cells. 
	
Sections of tissue was obtained from a hDAF+ CMAH-/- GGTA1-/-  (DKO CD55+) pig 
after euthanasia. Tissues were stained with anti-hCD55 [101] and a DAPI nuclear stain 
[75]. Top panels show tissue-level expression in heart. Bottom panels show cellular 
expression in PBMCs. Confocal settings were set to isotype control levels (left).  
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Figure 4.3: Human antibody binding directed towards porcine cells.  
	
PBMCs from CMAH-/- GGTA1-/-  (DKO), hDAF+ CMAH-/- GGTA1-/-  (DKO CD55+) or 
CMAH-/- GGTA1-/- B4GalNT2-/- [125] swine were incubated with 25% heat inactivated 
human sera from 10 healthy human donors for 1 hour at 4oC. Secondary flouresecent 
antibodies were used to detect IgG and IgM binding to the cells with median fluorescence 
intensity being evaluated (MFI). T-test statistical analysis was used to analyze the 
difference between genotype cohorts (n=10). Human IgG and IgM binding was not 
statistically affected by the presence of hCD55. Both IgG and IgM binding was 
statistically lower to the TKO animal. The level of antibody binding to TKO cells was 
reduced below the threshold at which we do not expect allograft antibody-mediated acute 
rejection to occur, as depicted by the horizontal line. A represents patterns of human IgM 
binding (n=10). IgM is binding is not a relevant metric for allotransplantation, and its 
significance to xenotransplantation remains in question. B represents patterns of human 
IgG binding (n=10).  
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Figure 4.4: Human antibody-mediated complement-depended cytotoxicity to 
porcine cells.  
	
Human sera was incubated in serial dilution with PBMCs from or CMAH-/- GGTA1-/- 
(DKO), DKO hCD55+ or CMAH-/- GGTA1-/- B4GalNT2-/- [125] swine. After wash, 
baby rabbit complement was added.  Cell death was measured by live/dead co-labeling 
for analysis by flow cytometry.  A represents the average percent cell death across animal 
cohorts at a 1/2 dilution. (n=10) B represents a nonlinear regression analysis of killing 
curves obtained from the seven-point dilution assay described. (n=10, R2 score=0.98) 
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Figure 4.5: Antibody-mediated complement-depended cytotoxicity is related to 
human IgM levels.  
	
Within the lytic assay described, the magnitude of difference between CMAH-/- GGTA1-/- 
(DKO) and CMAH-/- GGTA1-/- B4GalNT2-/- [125] cells varied for each human serum 
tested. The degree of separation between killing curves correlated to the degree of 
difference between human IgM binding across individual sera.  A represents the 
cytotoxicity of human serum 4 (above) and median IgG and IgM binding from serum 4 
(below). B represents the cytotoxicity of human serum 10 (above) and median IgG and 
IgM binding from serum 10 (below). Dashed lines indicate levels of 50% cell death as 
indicated by the linear regression model. 
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DISCUSSION  
	
Antibody mediated rejection (AMR) has been the barrier to clinical application of 
xenotransplantation. In 2003 the first GGTA1-/- pig was created, representing the first 
significant reduction to the AMR barrier and solidifying the importance of humanizing 
porcine carbohydrate profiles.[19, 32] The in vivo significance of this achievement was 
subsequently well described by work performed by Dr. David Cooper and colleagues; in 
2005 his group achieved life-supporting xenograft survival in baboons up to 6 months 
using GGTA1-/- porcine organs. [89, 126]  Despite this great achievement in the pig-to-
primate model, GGTA1-/- organs eventually failed in the context of thrombotic 
microangiopathy raising the possibility of residual non-Gal antigen-driven AMR.  
In the absence of other identifiable antigen targets, efforts to limit AMR of 
GGTA1-/- organs relied on a direct complement regulation strategy. [127, 128]  Within 
this climate, human CD55 and CD46 emerged as the central hCRPs for transgenesis. By 
disrupting the complement cascade pathway, these proteins enhance xenograft resistance 
to complement-mediated damage without affecting antibody binding. The protective 
effect of hCRP transgenes has been shown to be linearly proportional to expression level. 
[129] Subsequently, within a high antigen background, hCRP approaches have favored 
over-expression. [127] Alternatively, endogenous porcine complement regulatory 
proteins (pCRP) have also been shown to limit human C3b binding when overexpressed. 
[130, 131] 
More recently, advances have been made on the antigen-reduction front, that 
significantly reduce human and primate antibody binding to porcine cells. [38, 47] It has 
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therefore become essential to examine the potential for complement regulatory proteins 
to limit cytotoxicity within this new context of lower xenoantibody binding.  
The results of our study have several implications for the prospects of moving 
xenotransplantation to the clinic.  First, the CMAH-/- GGTA1-/- B4GalNT2-/- [125] pig 
exhibits very low levels of human IgG and IgM antibody binding and low levels of 
complement-mediated damage, even in the absence of a hCRP. The MFIs in the 
crossmatches of the TKO pigs suggest that the 10 subjects tested could receive a TKO 
pig organ transplant without the need for desensitization to avoid AMR.  This finding is 
significant since it removes a barrier that has limited progress in xenotransplantation for 
the last 25 years. [132, 133]   In allotransplantation the impact of IgM is not considered 
when evaluating the risk of AMR via crossmatching and donor IgM is removed from sera 
before analysis. [120]  It is unclear whether IgM is important in xenotransplantation, 
although two of the three longest surviving pig-to-non-human primate renal xenografts 
(136 and 310 days) had high levels of xenoreactive IgM. [71, 134] The survival of those 
two primates suggests that similar to allotransplantaion, xenoreactive IgG, and not IgM 
levels are the determinant of whether early AMR will occur.  
This study shows that hCRPs can limit in vitro complement-induced cytotoxicity 
even when the antigen level is low. Our results also show that antigen deletion can reduce 
complement-mediated injury to a greater extent than direct complement regulation. These 
findings are not completely unexpected in the context of previously published data. In 
2012 McGregor et al. noted that expression of hCD55 appeared to restrict local 
complement activation in a cardiac model of pig-to-primate transplant, but did not 
prolong graft survival. [135] Using a GGTA1-/- background, they noted considerable 
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antibody deposition and concluded that identifying and eliminating non-Gal antigens was 
still important. Conversely, recent work by Azimzadeh et al. suggests that the addition of 
a hCRP into a GGTA1-/- background can limit early graft failure in the pig-to-primate 
model. [136] Similarly, our findings support the assertion that hCRP expression limits 
antibody-mediated complement dependent cytotoxicity. Moreover, we show that 
complement-mediated damage can also be effectively minimized by silencing the 
GGTA1, CMAH and B4GalNT2 genes in concert.  Ultimately the human complement 
regulatory strategy may be most effective when combined with significant antigen 
reduction. Taken together, our results show that the reduction of antigen on the surface of 
pig cells will facilitate movement of xenotransplantation to the clinic.  
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CHAPTER FIVE: Modified glycan models of pig-to-human xenotransplantation do 
not enhance the human-anti-pig T cell response. 
INTRODUCTION  
	
Historically humoral immunity has been the barrier to clinical application of pig-to-
human xenotransplantation. The previous chapter describes a modified porcine glycan 
model that reduces human antibody binding to levels comparable with current allograft 
standards. The newly described genetic background provides an answer to the problem of 
acute humoral xenograft rejection (AHXR). From this unprecedented position of humoral 
acceptability, it is subsequently important to consider the impact these modifications may 
have on measures of cell-mediated rejection. 
The previous chapters have described strategies that modify the porcine genome 
in ways that limit the xenogenic humoral response. As xenotransplantation moves closer 
to clinical application, cellular immunity remains an increasingly relevant consideration. 
Acute humoral rejection is avoided in allotransplantation by judicious selection of 
appropriately matched donor-recipient pairs; utilizing IgG and complement-dependent 
cross match assays similar to those described in chapters 3-5, favorable HLA antigen 
profiles are screened for across a diverse donor pool. However, cellular immunity still 
affects allotransplantation -largely through MHC-dependent pathways- and is 
conventionally controlled through pharmacologic maintenance of recipient 
immunosuppression. One ancillary advantage of the strategies for model animal creation 
described in chapters 2-5 is that they efficiently create clonal lineages; in this manner the 
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study of human-anti-porcine cellular immunity is arguably more universally translatable 
to clinical application than the study of allotransplant cellular rejection; in the pig-to-
human models proposed, the donor antigen profile can be held as a controlled variable.   
 Unlike the process of matching allografts with recipients, porcine xenografts are 
affected by an inherent immunologic discordance that is associated with traversing the 
evolutionary divide across species; described in previous chapters, wild-type swine cells 
exhibit a carbohydrate profile to which humans have pre-formed antibodies. Unmodified, 
these antigens cause acute humoral xenograft rejection (AHXR) in a pig-to-primate 
model. The creation of GGTA1-/- (GTKO) pigs in 2002 marked the first successful 
antigen reduction and legitimized the concept of pig-to-human xenotransplantation. [19] 
Over the past 15 years, many genetic modifications have been attempted to overcome 
AHXR. As described in chapter four, the creation of a triple-knockout animal 
successfully lowered human antibody binding to levels comparable with currently-
accepted allograft standards.  [27]   
Since the development of the first GGTA1-/- pig, there has been uncertainty about 
the severity of the human-anti-pig T cell response and whether it can be adequately 
controlled using approved immunosuppressive therapies. [137] In vivo, pig-to-primate 
solid organ transplant has been sustained using a wide range of pharmacologic strategies. 
[138] Unfortunately, the enduring efficacy of these regimens has been difficult to 
ascertain, as graft rejection often occurred early in the context of high xenoantigen level 
and thrombotic microangiopathy [139]. As such, discussions of cell-mediated rejection 
have not commanded the same attention afforded to problems of AHXR.   
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Advances in genetic engineering strategies have dramatically sped the process of 
identifying and eliminating xenoantigens.[115] Within the porcine genome, the GGTA1 
locus drives αGal glycan expression and the CMAH gene drives Neu5Gc glycan 
expression. Each of these gene products independently induces human antibody binding; 
when both genes are silenced, human IgG and IgM binding is dramatically lowered. [38]   
As these porcine cells now react similarly to human cells in crossmatch analysis, it is 
increasingly likely that xenograft AHXR can be effectively mediated by genetic donor 
modification; discussions of cell-mediated rejection pathways should now occupy a more 
prominent position within the study of xenotransplantation.  
Though the dedicated study of glycoimmunology is relatively new, a growing 
body of evidence supports the ability of glycosylation variance to affect immune 
response;[140] modifications made to mammalian glycan profiles warrant careful 
consideration of the potential for immunogenic effects. Herein we describe the impact of 
successful glycan antigen-reduction models of pig-to-human xenotransplant in a cell-
mediated proliferation assay. As these genetically modified cells have shown great 
promise by reducing antibody-mediated barriers of AHXR, their cell-mediated 
immunogenicity is of potential clinical importance.  
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MATERIALS AND METHODS 
 
Modified Porcine Cell Construction 
Genetically modified pigs were created utilizing a CRISPR/Cas9 approach and somatic 
cell nuclear transfer as previously described by Li et al. [24] Briefly, bicistronic CRISPR 
sgRNA expression vectors co-expressing the Cas9 gene were designed to bind and cleave 
the GGTA1 gene beginning at position 293654066 of NC_010443.4 (forward: 
CACCGCGAAAATAATGAATGTCAA) and CMAH gene beginning at position 
210555038 of NCBI reference NC_010449.4 (forward: 
CACCGAGTAAGGTACGTGATCTGT). Porcine liver-derived cells were cultured, and 
transfected with targeted nuclease-expressing vectors using the Neon transfection system 
(Life Technologies, Grand Island NY, USA) as described by Lutz et al. [38] After 
negative selection by flow cytometry,  knockout cells were identified and somatic cell 
nuclear transfer (SCNT) was used to create clonal animals from modified porcine cells. 
Genetically modified animals were grown to maturity and served as source of peripheral 
cells for analysis by blood draw. The Institutional Biosafety and Institutional Animal 
Care and Use Committee at Indiana University School of Medicine approved the use of 
animals in this research.    
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Preparation of Stimulator Populations 
Porcine blood was obtained by venous sample from wild type (WT), GGTA1-/- (GTKO) 
or CMAH-/- GGTA1-/-(DKO) animals. Human buffycoats were obtained from a local 
blood bank. PBMCs were isolated from these samples by Ficoll-Paque centrifugation 
(GE Health, Uppsla, Sweden) and assessed for viability using Trypan blue.  These cells 
were then treated with mitomycin C at a concentration of 25ug/ml/4E6 cells for 30 
minutes at 37 degrees C. 10 uL/ml of DNase added for the last 5 minutes of incubation. 
After mitomycin C treatment, the cells were washed three times with HBSS, counted by 
hemocytometer and brought to a final concentration of 2E6/mL in AIM V media 
(ThermoFischer, Grand Island, NY).  
 
Preparation of Responder Populations 
Human buffycoats were obtained from a local blood bank and PBMCs were isolated from 
these samples by Ficoll-Paque centrifugation. (GE Health, Uppsla, Sweden) Viability 
was assessed using Trypan blue. Isolated cells were washed three times with HBSS and 
brought to a final concentration of 2E6/mL in AMI V media. To control for inter-
individual variability in human responders, three human samples were prepared and 
tested for each stimulator.  
 
BrdU ELISA based Mixed lymphocyte reaction (MLR) assay 
A 96 well micro-titer plate (MTP) was used for mixed lymphocyte reaction over a 5 day 
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period was set up and incubated for four days. All responder cells were added at a 
concentration of 200,000 PBMCs/well. All stimulator cells were added at a concentration 
of 200,000 PBMCs/well. Bromodeoxyuridine (BrdU) was then added for an overnight 
incubation and on day five a BrdU ELISA was performed utilizing a Roche ELISA 
proliferation kit following the manufacturers protocol (Roche Diagnostics, Indianapolis 
IN). Absorbance was read on a Dynex MRX plate reader at 450nm (MTX Lab Systems, 
Vienna, VA). Allogeneic reactions consisted of human PBMC responder cells with 
human mitomycin C treated PBMC stimulator cells. Xenogeneic reactions consisted of 
human responder cells with mitomycin C treated porcine PBMCs. Positive controls 
consisted of human or porcine PBMC responder cells with 2 ug/well of 
phytohemagglutinin [141]. Negative controls consisted of human or porcine mitomycin C 
treated PBMCs. Simulation index was calculated by absorbance of proliferation response 
of experimental treatment / absorbance of proliferation of PBMCs alone. As a proof of 
concept for pharmacologic intervention, DKO-stimulated xenogeneic reactions were 
preformed in the presence of dexamethasone against an allogeneic control; in the absence 
of relevant clinical plasma levels for dexamethasone, concentration was chosen on the 
basis of previous in vitro study. [142-144] Each stimulator-responder pair was tested in 
triplicate; differences across groups were analyzed using a one-way analysis of variance. 
 
Immunosuppressive treatment during MLR 
A flow cytometric proliferative assay was performed to complement our DNA-synthesis 
measurements; by directly labeling responder cells, this approach directly examined 
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proliferative potential over a broad time course in the presence or absence of clinically 
relevant pharmacologic intervention. To better characterize the effect of 
immunosuppression on the direct xenogeneic human T cell response to GGTA1-/- 
CMAH-/- (DKO) cells, human CD4 T cells were isolated using human CD4 T isolation 
kit (Miltenyi Biotec Inc., San Diego, CA, USA), and labeled with CFSE using 
CellTrace™ CFSE Cell Proliferation Kit (Life Technologies, NY, USA). Splenocytes 
from human or GGTA1-/- CMAH-/- (DKO) pigs were used as stimulating populations; 
they were labeled using CellTrace™ Far Red DDAO-SE (Life Technologies, NY, USA), 
and irradiated by Gammacell-1000 Irradiator at 3000 Gy. Human CD4+ responders at 
1x105 cells/well in 96-well round-bottom plates (Corning, Lowell, MA, USA) were co-
incubated with or without irradiated stimulators [145]. CFSE-labeled CD4 T cells were 
co-cultured with FarRed labeled splenocytes (R:S=1:8) in serum-free AIM V® Medium 
(Life Technologies, NY, USA) in the presence or absence of immunosuppressive agents 
dosed for clinical relevance: 10ng/ml FK-506 (FK, LC Laboratories); 10ng/ml 
Rapamycin (RAPA, InvivoGen); 200ng/ml Cyclosporin A (CsA, LC Laboraories). 
Analysis of proliferation was limited to live human T cells by light scatter gating and far-
red exclusion of stimulator cells; an non-stimulated, non-suppressed human T cell control 
was included with each experiment.  All tests were repeated in triplicate under identical 
conditions. 
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RESULTS  
 
Creation of modified porcine cells 
CRISPR/Cas9-directed mutagenesis created targeted disruptions at the GGTA1 and 
CMAH loci. (Figure 5.1) All disruptions produced a null phenotype at the loci of interest, 
and have been previously published by Li et al. [24] After phenotype selection and 
SCNT, these cells created healthy clonal animals. Animals used in this study were of a 
WT, GGTA1-/- (GTKO), or CMAH-/- GGTA1-/- (DKO), background. The viability of all 
PBMCs obtained was above 97% by trypan blue staining.    
 
Figure 5.1: Targeted Genetic Disruptions 
	
CRISPR/Cas9-directed mutagenesis created targeted disruptions at the GGTA1 and 
CMAH loci.  A) Depicts a 7bp deletion within the GGTA1 locus B) Depicts a 
simultaneous 3bp deletion and 5bp insertion at the CMAH locus. All modifications 
produced a null phenotype.  
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BrdU ELISA based Mixed lymphocyte reaction (MLR) assay 
Human and porcine PBMC cultures showed positive PHA proliferative responses 
whereas mitomycin C treated PBMCs had stimulation indexes (SI) less than baseline 
PBMC cultures (SI<1.0). Human responder PHA control groups exhibited a SI of 7.6, 
porcine PHA control groups exhibited SI ranging from 38.2 – 103.0. No evidence of 
overgrowth was noted throughout experimental wells. Allogeneic and xenogeneic 
responses to a one-way mixed lymphocyte reaction were comparable. The allogeneic 
response was positive with a stimulation index of 5.8. A xenogeneic response was seen 
for all tested cell stimulator populations with a stimulation index range of 5.5-7.1.  Figure 
5.2 depicts stimulation indices for the tested stimulator populations.  Differences between 
porcine stimulator cells failed to reach statistical significance (p=.0529). Although the 
WT xenogeneic reaction was 16% stronger than the allogeneic reaction (p=.0023), the 
difference between an allogeneic reaction and genetically modified porcine cell-
stimulated xenogeneic reactions failed to reach significance (p=0.15).  
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Figure 5.2: Stimulation Indices of allogeneic and xenogeneic mixed lymphocyte 
reactions 
	
Represents the results of a one-way mixed lymphocyte reaction with a human responder 
population. Stimulator Populations varied and included human, wild-type porcine, or 
modified porcine cells of a GGTA1-/- (GTKO) or GGTA1-/- CMAH-/- (DKO) background.  
Positive controls consisted of human PBMC responder cells with 2 ug/well of 
phytohemagglutinin [141]. Negative controls consisted of human responder cells 
mitomycin C treated (MitC). Each stimulator-responder combination was repeated in 
triplicate under identical conditions. 
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As shown in Figure 5.3, both allogeneic and xenogeneic reactions were reduced to the 
level of background by the addition of 0.05uM of dexamethasone. Differences in 
dexamethasone-suppression between xenogeneic and allogeneic reactions were not 
significant (p=0.078). 
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Figure 5.3: Stimulation Indices of allogeneic and xenogeneic mixed lymphocyte 
reactions in the presence of dexamethasone. 
	
Represents the results of a one-way mixed lymphocyte reaction with a human responder 
population with and without dexamethasone (DEX) stimulation. Stimulator Populations 
varied and included human, or modified porcine cells of a GGTA1-/- CMAH-/- (DKO) 
background.  Positive control consisted of human responder cells with 2 ug/well of 
phytohemagglutinin [141]. Each stimulator-responder combination was repeated in 
triplicate under identical conditions. 
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Effect of Immunosuppression on xenogenic human CD4 T cell proliferation in vitro. 
Immunosuppressive drugs are used clinically to prevent immune rejection in 
allotransplantation. Given our ability to limit the human-anti-porcine cellular response in 
a CMAH-/- GGTA1-/-  (DKO) model with dexamethasone, we sought to further 
characterize the clinical relevance of these findings. Plasma dexamethasone levels are not 
routinely followed clinically, post transplantation; this challenges the translation of 
information from in vitro assay. FK-506, RAPA, and CsA however, all have published 
plasma levels that can more easily correlate in vitro work to the clinic. [139, 146, 147]  
To assess the ability of these immunosuppressant agents to inhibit the direct xenogeneic 
human T cell response to glycan-modified porcine cells, a flow cytometry-based MLR 
assay was performed (Figure 5.4). Human CD4 T cell expansion was successfully 
induced by exposure to pig splenocytes; this xenogeneic reaction was significantly 
inhibited by independent addition of FK-506, RAPA and CsA. 
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Figure 5.4. Effect of Immunosuppression agents on human T cell proliferation.	 
	
A flow cytometry-based MLR assay was performed using CFSE labeled human CD4 T 
cells as responders, and FarRed labeled human or GGTA1-/- CMAH-/- (DKO) pig 
splenocytes as stimulators. The culture medium was in the presence or absence of 
clinically relevant doses of immunosuppressant including 10ng/ml FK-506, 10ng/ml 
RAPA and 200ng/ml CsA.  Proliferation of human CD4+T cells were quantified by 
CFSE dilution on day 7. Analysis of proliferation was limited to live human T cells by 
light scatter gating and far-red exclusion; an unstimulated human T cell control without 
immunosuppression was included with each experiment (Grey). Pharmacologic 
mediation of the xenogeneic T-cell response was equivalent to the allogeneic T-cell 
response for all drugs tested.  Representative histograms are shown. Experiments were 
repeated in triplicate under identical conditions. 
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DISCUSSION  
 
As described in chapter one, the solid organ transplant community is gravely affected by 
a growing shortage of solid organs. Although considerable work has been done to make 
better use of available allografts, a recent study by Rana et al. notes that we have reached 
a plateau in the volume of all solid organ transplants. [148] From this position, answering 
the problem of a growing transplant list will require a supply-side addition to the donor 
pool. Utilizing the advanced techniques of genetic engineering described in chapter two, 
modification of pigs as surrogate organ donors represents the most immediate solution.  
The porcine GGTA1 and CMAH genes are each independently responsible for 
driving human antibody binding to porcine cells.  Recently, simultaneous knockouts of 
these genes have reduced human antibody binding towards porcine cells to the point at 
which of acute humoral xenograft rejection (AHXR) would not be expected. [27, 38]  
Examining remaining barriers -beyond AHXR- to the clinical application of these models 
requires a consideration of the human-anti-porcine cell-mediated response to genetically 
modified pigs.  
There has historically been some uncertainty about the severity of the xenogeneic 
T-cell response. Initially, xenogeneic cell-mediated responses were thought to be less 
proliferative than allogeneic reactions. [149-151] Due to differences between MHC 
molecules across species, xenogeneic cell-mediated rejection was not considered to be a 
significant barrier to clinical application. Although this theory was supported by early 
mouse-anti-human models, [152] more recent work has demonstrated xenogeneic cell-
mediated responses to be comparable to allogeneic reactions.  [153-155] The present 
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results support the previous conclusions of Yamada et al. [156] who demonstrated that 
the human-anti-porcine xenogeneic cell-mediated response was similar in strength to an 
allogeneic response.    
Although the role of carbohydrates in cell-mediated immune response pathways 
are incompletely understood, any alteration in donor glycan profiles has the capacity to 
alter recipient T-cell response through both direct and indirect pathways. [157, 158] The 
genetic modifications in question within this study were of particular theoretical 
relevance to the human-anti-porcine cell-mediated response, as they alter sialic acid 
profiles. Of the various roles sialic acids play, their role as ligands of inhibitory sialic 
acid–binding Ig superfamily lectins (siglecs) provides a unique potential to affect the 
human immune system. [159] Siglecs drive negative feedback signals to dampen cell-
mediated immune responses. [160] Recently, humanizing sialic acid profiles of animals 
has demonstrated unexpected effects on the T cell response. With particular relevance to 
our model, it has been shown that ‘humanized’ CMAH-/- mice mount a hyperactive T cell 
response compared to WT mice. [161] Because imposing a human glycosylation 
mutation pattern onto porcine cells is imperative to avoid AHXR, it is important to 
directly study the effect that these mutations may have on cell-mediated human response. 
The present study is the first to show that silencing the porcine GGTA1 and CMAH 
genes does not negatively impact the human-anti-porcine cellular response. One reason 
that these genetic modifications do not raise the barrier of cellular immunity, may be that 
-under genetic pressure- the corresponding human siglec receptor profile has also been 
altered. [162, 163] In the absence of the appropriate receptors, the presence or absence of 
these unique sialic acid glycan caps are irrelevant to the human responder. Moreover, this 
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implies that there is likely no cross reactivity of GGTA1 or CMAH gene products to 
other receptors within the human siglec profile.   
In vivo, pig-to primate xenotransplantation has been studied using a variety of 
immunosuppressive regimens. Unfortunately, clinical inferences from pig-to primate 
models are challenged by an inherent difference in proliferative potential between 
humans and non-human primate and the fact that many of these studies have utilized 
immunosuppression not suitable for human use. [164] As such, it is important to study 
the relevant genetic models of xenotransplantation –and their reaction to clinically 
available immunosuppression- within an in vitro pig-to-human model whenever possible. 
Given that human cellular responses to the porcine knockout models were not 
significantly different from the allogeneic response, it seems likely that standard 
pharmacologic regimens should provide effective immunomodulation.  
At the most elemental level, this data further supports the clinical application of 
carbohydrate knockout models of pig-to-human xenotransplantation.  We have previously 
published a significant reduction in human IgG and IgM binding directed towards 
GGTA1-/- CMAH-/- porcine cells. [27] As antibody-mediated immune injury is the 
principle driver of early graft injury and AHXR, these modifications overcome a pivotal 
barrier to pig-to-human xenotransplantation. In the present study, we show that silencing 
the GGTA1 and CMAH genes have no deleterious effect on the cell-mediated pathway of 
rejection.  Furthermore, we show that the human T cell response to these knockout pigs is 
capable of being mediated by conventional immunosuppression. Although more work 
must be done to solidify an appropriate combination of immunomodifiers, this 
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information represents a promising start for the study of human cellular immunity to 
genetically modified pigs.    
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CHAPTER SIX: The fate of human platelets exposed to porcine renal endothelium: 
a single-pass model of platelet uptake in domestic and genetically modified porcine 
organs. 
INTRODUCTION  
	
The genetic modification strategies described in chapters 2-5 offer great promise to the 
clinical application of pig-to-human xenotransplantation; with new strategies to 
overcome both humoral and cellular xenograft rejection, it has now become relevant to 
consider potential physiologic organ-specific barriers to clinical application. 
Thrombocytopenia may represent a significant challenge to the clinical application of 
solid-organ xenotransplantation.  When studied in a pig-to-primate model, consumptive 
coagulopathy has challenged renal xenografts. Described in chapters 3-5, new strategies 
of genetic manipulation have altered porcine carbohydrate profiles to significantly reduce 
human antibody binding to pig cells. As this process continues to eliminate immunologic 
barriers to clinical xenotransplantation, the relationship between human platelets and pig 
organs must be considered. 
If xenotransplantation using genetically modified porcine organs is to eliminate 
the shortage of donor organs for transplantation, both immunologic and physiologic 
barriers to clinical application must be understood.  As previously discussed, antibody 
mediated rejection (AMR) has made it impossible to move to the clinic with 
xenotransplantation.  Chapters 3-4 examine the importance of two important 
xenoantigens to which humans have xenoreactive antibodies, gal-α-(1,3)-gal, and N-
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glycolylneuraminic acid (Neu5Gc).  These xenoantigens are produced by enzymes that 
are present in humans and pigs, but in humans, gene activity has been silenced during the 
course of evolution.  α-1,3-galactosyltransferase (GGTA1) produces the Gal α(1,3) Gal 
epitope, and the development of GGTA1-/- pigs eliminated 70-85% of the xenoreactive 
antibodies that humans have as a barrier to xenotransplantation.  The cytidine 
monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene produces Neu5Gc.  
The creation of GGTA1-/- CMAH-/- pigs has reduced human antibody binding to the point 
where the crossmatch of pigs with humans is more favorable than a primate-to-human 
crossmatch. [29] More recently, as described in chapter four, the creation of GGTA1-/- 
CMAH-/- B4GalT2-/- pigs have reduced levels of antibody binding to the point that 80% 
of patients on transplant lists would not be expected to have early AMR. As current 
models of pig-to-human xenotransplantation have reached immunologic equivalence to 
allografts, it is now important to carefully consider potential organ-specific barriers to 
xenotransplantation.  
The most well characterized organ-specific challenge to xenotrasplantation is 
thrombotic microangiopathy (TMA). This phenomenon is organ-dependent as it ranges 
from graft-limiting thrombotic microangiopathy in kidney models to consumptive 
coagulopathy in a liver model of pig-to-primate xenotransplanation. Porcine GGTA1-/- 
kidneys transplanted into non-human primates (NHP) are not hyperacutely rejected, but 
they do still fail because of AMR.  The AMR seen in GGTA1-/- -to-primate 
transplantation is most notably characterized by thrombotic microangiopahty. [165] 
However, it remains unclear whether the TMA seen in GGTA1-/- -to-primate 
xenotransplantation occurs because of AMR, or is due to coagulation dysregulation based 
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on species incompatibilities in thromboregulatory pathways. As previously described by 
Burlak et al., an unmodified porcine liver retains the capacity to consume human platelets 
in the absence of immunologic injury; this raises the possibility of an aberrant 
relationship between the human platelet and porcine endothelial surface.  Although the 
mechanism of this interaction remains unclear, there is significant data that suggests pig 
VonWillebrand factor (vWf) may aggregate human platelets in the absence of immune 
mediated injury or shear force. [166]  As shown in figure 6.1, differing glycosylation 
patterns between pig and human vWF A1 domain may affect the affinity of human 
platelet GpIba receptor.  
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Figure 6.1: Porcine Von Willebrands Factor A1 Domain. 
	
The porcine Von Willebrands factor (vWF) differs from the human protein in the 
glycosylation patterns of the A1-domain. A) Human vWf incorporates a N-linked pattern 
[75] B) Porcine vWF incorporates an O-linked glycosylation pattern [101]. As this region 
is responsible for interaction with the GpIb receptor on human platelets, it has been 
suggested that this difference may lead to aberrant interactions.   
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Although it is clear that graft modifications will be necessary to circumvent the 
hypercoaguable interaction between porcine liver endothelium and human platelets, no 
information has existed regarding the porcine renal endothelium and human platelets. 
The recent success of pig-to-primate renal transplants for several months without 
coagulopathy has suggested that unlike the porcine liver, the porcine renal endothelium is 
relatively inert in the absence of immune injury. [71, 167] As xenotransplantation 
continues to move towards clinical application, it is important move beyond primate 
models whenever possible, and to specifically consider pig-to-human interaction; this 
represents the first study to characterize the interaction between human platelets and the 
porcine kidney.  The experiments in this report evaluated whether human platelets 
perfused through pig kidneys are retained in the absence of an immunologic injury.  The 
results have important implications for the direction of further genetic modification of 
donor pigs. 
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MATERIALS AND METHODS 
 
Creation of genetically modified pigs 
Cas9 nuclease mediated gene editing with multiple guide RNAs was employed for the 
efficient production of genetically modified pigs. As previously described, CRISPR 
Guide RNAs were designed to target the CMAH and GGTA1 genes, responsible for the 
production of known xenoantigens, Neu5Gc and αGal. [78] Porcine liver-derived cells 
were co-transfected with these CRISPR/Cas9 constructs using the Neon transfection 
system (Life Technologies, Grand Island NY). After the IB4 counter selection, cells 
bearing CMAH and GGTA1 mutations were enriched and further confirmed by DNA 
sequencing analysis. These cells were used as nuclear donors for somatic cell nuclear 
transfer (SCNT) to achieve pregnancy in a surrogate mother. [38] All the animals used in 
this study were approved by the Institutional Biosafety and Institutional Animal Care and 
Use Committee of IUPUI. 
 
Isolation and staining of autologous (donor animal) platelets for perfusion 
500ml of porcine blood was collected into tubes containing acid-citrate-dextrose at the 
time of surgery. After centrifugation (5 minutes at 2,000g) the top two thirds of platelet-
rich plasma was removed and centrifuged (5 minutes at 5,000g). The pellet was 
resuspended in PBS/ACD 50:1 and washed twice. 10^10 platelets were obtained by count 
on hemocytmoeter, of which 2.5^10 were labeled with carboxyfloroscine succinimidyl 
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ester (CFSE) (Invitrogen, Grand Island, NY).  All platelets were brought up to a final 
concentration of 10^10/L in Krebs solution. 
 
Isolation and staining of human platelets  
One unit of human platelets was purchased from a local blood bank. Platelet isolation 
was performed to remove human antibody. The platelets were transferred to 50ml conical 
tubes and centrifuged (5 minutes at 5,000g). The pellet was resuspended in PBS/ACD 
50:1 and washed twice. 10^10 platelets were obtained by count on hemocytmoeter, of 
which 2.5^10 were CFSE-labeled (Invitrogen, Grand Island, NY) as described by Paris 
and Chihara. [168] All platelets were brought up to a final concentration of 10^10/L in 
Kreb’s solution.  
 
Procurement and preparation of porcine organs 
Kidneys were obtained from healthy domestic, GGTA1-/-, and GGTA1-/- CMAH-/- pigs.  
Livers were obtained from healthy domestic animals as a positive control. After 
euthanization, the abdomen was entered; the abdominal aorta was identified and 
cannulated below the renal arteries. The aorta was clamped above the renal arteries and 
an intracorporeal flush was preformed with HTK solution (Essential Pharmaceuticals, 
Ewing, NJ, USA).   Both kidneys were removed enbloc and divided on the backbench to 
accommodate an additional flush of 500ml HTK into each renal artery. Each renal artery 
and vein was cannulated and ureters were fenestrated.   Livers were procured in a similar 
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fashion, with 4L of intracorporeal flush and 1-2L of backbench HTK flush. Organs 
remained on ice after procurement. Cold ischemic time between procurement and platelet 
perfusion did not exceed 3 hours.    
 
Perfusion of organs 
Procured kidneys were cannulated to achieve definitive control of the ureter, renal artery 
and vein. Kidneys were weighed and warmed to a controlled temperature range of 35-37 
°C  by perfusion with warmed Kreb’s solution with 1ml/L heparin. This step also 
removed any remaining autologous platelets. Directly after warm flush, temperature was 
verified by IR thermometer (Fluke Corp, Everett WA). 1L of CFSE-labeled platelets was 
perfused through the renal artery. The right and left kidney was randomly assigned to 
receive either human or autologous platelets. A pre-perfusion sample was obtained 
proximal to the renal artery at time zero. Thereafter samples were collected into a 
polypropylene flow tube from renal vein outflow every 50 mL. Urine output was 
measured by direct cannulation of the ureter. All renal perfusions were repeated in 
biological triplicate for each data point collected. A single pass model of liver perfusion 
was preformed on WT porcine livers as previously described by Paris et al. [67] to 
confirm the ability of fluorescence sampling to appropriately measure platelet 
disappearance in a model known to consume platelets. Owed to the higher flow rates 
achieved through liver, hepatic perfusion was time-limited rather than volume limited, 
and served to demonstrate the capacity of CFSE-labeling and fluorescence monitoring to 
detect human platelet uptake within a single-pass model. Hepatic perfusions were 
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repeated in biological triplicate for each data point collected. Tissue biopsy was obtained 
directly after platelet perfusion of livers and kidneys for confocal microscopic analysis.   
 
Measuring of Fluorescence  
Samples obtained from venous outflow were read on a Spetramax M2 fluoresce plate 
reader (Molecular Devices Corp., Sunnyvale, CA, USA). A control lane for each 
perfusion was established by creating a serial dilution by halves from each organ’s pre-
perfusion sample. 100ul from each venous sample obtained was sequentially plated to 
create experimental lanes. Nine consecutive readings were obtained from each sample 
collected and relative fluorescence values [121] were recorded as median 488 emission. 
Data output was analyzed on Prism software (Graphpad Software Inc., La Jolla, CA). 
Output was reported as % maximal fluorescence using the equation: y=  (venous output 
fluorescence/ arterial input fluorescence)*100. Differences between human and 
autologous cohorts were analyzed across cohorts for statistical significance using a two-
way ANOVA.  Urine output from renal perfusions was recorded and calculated as a 
percentage of flow for each sample point using the equation: [[total urine output 
(L)/1]/number of volume measurements obtained]*100.   
 
Confocal for Biopsy 
Mounted tissues from post-perfusion biopsies were blocked in Odyssey blocking buffer 
(LI-Cor Biosciences, Lincoln, NE, USA) in HBSS for 1 h. The slides were then fixed in 
4% paraformaldehyde for 10 min. Tissues were stained with CD31 (Invitrogen, Grand 
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Island, NY) to visualize the endothelial surface, followed by three HBSS washes and 
Donkey anti-Chicken DyLight 649 (Jackson Immuno Research Laboratories Inc., West 
Grove, PA). Tissues were incubated with secondary antibody for approximately 1 hour 
and then washed three times with 0.1% HBSS Tween. DAPI (Invitrogen, Grand Island, 
NY) was added to all slides for 1 min. as a nuclear stain followed by two 0.1% HBSS 
Tween washes. Tissues were mounted in ProLong Gold (Invitrogen, Grand Island, NY). 
Confocal microscopy was performed using an Olympus FV1000 (Olympus America Inc., 
Center Valley, PA, USA). All obtained samples were viewed (n=3 for each experimental 
group), captured images were representative of all samples viewed.  
 
In Vitro Platelet Up-Take 
Primary LSEC and REC isolation 
A porcine liver and kidney were procured from a single domestic animal as previously 
described.[168] Briefly, each organ was placed in a chilled dish (4 °C) and then flushed 
with 0.025% of collagenase type IV from Clostridium histolyticum (Sigma, St. Louis, 
MO) at 37 °C followed by continued perfusion with collagenase at 37 °C for 20 min. 
Perfusion was paused for 30 min and collagenase was carefully removed from around 
organ and vessel sites. Perfusion was resumed at 10 ml/min for 45 min with gentle 
manipulation of the organ to assure even digestion. Enzyme activity in the perfusate was 
immediately quenched by the addition of 1/10 volume new born calf serum. The 
perfusate was centrifuged at 400 g for 10 min at room temperature. The cell pellet 
containing the LSEC or REC was saved and resuspended in RPMI medium supplemented 
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with 0.02% (w/v) EDTA. The cell suspension was centrifuged again at 400 g for 10 min 
at 4 °C. The pellet was resuspended in EC culture medium (RPMI medium supplemented 
with 10% fetal bovine serum (v/v), 100 µg/ml endothelial cell-specific growth factor, 
penicillin, streptomycin, and amphotericin B) and plated onto clear-bottomed cell culture-
treated microscopy slide wells (100, 000 cells/well initial concentration). Medium was 
changed each day for 2 days, and all cells were utilized on day 4 after isolation. 
 
Confocal analysis of endothelial lines  
Primary LSEC and REC lines from a healthy domestic animal were cultured for 4 days at 
37 °C and 5% CO2 in clear-bottomed cell culture-treated microscopy slide wells 
(100, 000 cells/well initial concentration). Fresh human platelets were isolated from a 
healthy donor and labeled (CFSE) as described above.   Four million CFSE-labeled 
platelets were added to experimental wells containing primary endothelial cells and 
media. Slides were incubated with platelets for 15, 30, 60 minutes. Duplicate wells for 
each time point were washed with 150 µl of PBS three times then fixed with 50 µl of 4% 
paraformaldehyde–PBS solution for 20 min. Cells were stained with Chicken anti-Pig 
CD31 (Invitrogen, Grand Island, NY) to visualize the endothelial surface, followed by 
three HBSS washes and Donkey anti-Chicken DyLight 649 (Jackson Immuno Research 
Laboratories Inc.). Tissues were incubated with secondary antibody for approximately 
1 h and then washed three times with 0.1% HBSS Tween. DAPI (Invitrogen, Grand 
Island, NY) was added to all slides for 1 min as a nuclear stain followed by two 0.1% 
HBSS washes. Tissues were mounted in ProLong Gold (Invitrogen, Grand Island, NY). 
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Confocal microscopy was performed using an Olympus FV1000 (Olympus America Inc., 
Center Valley, PA, USA).  Experiments were performed in triplicate for each cohort and 
images reported were representative of all images viewed (n= 16 for each cohort).  
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RESULTS  
	
DNA sequencing analysis of the cloned pigs 
Pig liver-derived cells transfected with nuclease-targeting knockout vectors for GGTA1 
and CMAH genes exhibited gene-silencing mutational events; IB4 lectin-conjugated 
beads and sequence analysis facilitated the isolation of successfully mutated cells.  These 
cells were used to create healthy clonal animals by SCNT. As shown in figure 6.2, the 
animals used in this analysis exhibited a GGTA1-/- or GGTA1-/- CMAH-/- genotype. The 
phenotypes of these animals have been previously published by Li et al. [78] 
  
	120 
 
Figure 6.2: Genotype of Genetically Modified Pigs.  
	
A) depicts an animal carrying a 15bp deletion interrupting the CMAH gene and a single 
bp insertion disrupting the GGTA1 gene. B) depicts an animal carrying an unmodified 
CMAH gene and a single base insertion in the GGTA1 gene.  All depicted mutations 
created a frame shift mutation and a null phenotype with respect to the locus of interest.  
 
Analysis of human platelet uptake  
Human platelets were not removed by the porcine kidney in a single-pass model of 
perfusion under normothermic conditions. As displayed in figure 6.3, the % maximal 
fluorescence of human platelet samples measured from renal venous sampling did not 
significantly deviate from the platelet control values  (autologous cohort n=3, human 
platelet cohort n=3 for each genetic background). Differences between human and 
porcine platelet loss through the system failed to reach statistical significance in each 
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cohort (WT p= 0.15, GGTA1-/- p=0.12, GGTA1-/- CMAH-/- p=0.25). Median renal 
perfusion time was 28 minutes (range 26-34) and was not statistically different between 
cohorts. Similarly, median urine output per sample point did not vary significantly 
between cohorts and accounted for 0.4% of filtered volume (range 0.31- 0.52%). When 
compared to a single-pass model of hepatic platelet uptake as shown in figure 6.3D, the 
absence of renal platelet consumption is underscored. Within this study, the unmodified 
porcine liver consumed human platelets in a single-pass model of platelet perfusion in 
fewer than 10 minutes. WT suprahepatic inferior vena cava fluoresce reached a 
maximum of just 76% of input fluoresce within the human platelet cohort and was 
significantly lower than the autologous platelet control cohort (p=0.001).  Autologous 
platelet control groups failed to significantly differ between renal and liver perfusions 
(p=0.92), suggesting appropriate continuity between systems.  
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Depicts % input fluorescence (y axis) 
of samples drawn from venous output 
obtained at regular intervals (x axis). 
All values depicted are normalized to 
the experiment’s pre-infusion sample 
and were obtained using the equation 
y= input fluorescence/output 
fluorescence)*100. All experiments 
were repeated in biological triplicate, 
mean data points and standard error 
are displayed. A) Human and 
autologous platelets passed through 
domestic porcine kidneys. B) Human 
and autologous platelets passed 
through GGTA1-/- porcine kidneys. C) 
Human and autologous platelets 
passed through GGTA1-/- CMAH-/- 
porcine kidneys. D) Human and 
autologous platelets passed through 
domestic porcine livers.    
Figure 6.3:  A single pass model of 
platelet uptake. 
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Confocal analysis of tissue biopsies obtained after single-pass perfusions with CFSE-
labeled plates confirm the relationships presented by the single-pass results (Figure 6.4). 
These images depict an absence of human platelets associating with porcine renal 
endothelium, compared to a strong association noted between human platelets and 
porcine liver endothelium.   
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Figure 6.4: Biopsy Samples from human platelet perfusion.  
	
Biopsy samples were obtained from kidneys post-perfusion with CFSE-labeled human 
platelets. In all three types of kidneys perfused (wild type, GGTA1-/- and GGTA1-/- 
CMAH-/-), human platelets were not visible after post-perfusion flush. A wild-type liver 
was used as a positive control; here platelets are visible after post-perfusion flush. Images 
are representative of all samples viewed (n=3 for each perfusion).  
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The results of the in vitro platelet uptake assay preformed also confirm the 
relationships presented by single-pass results. When studied in vitro, CFSE-labeled 
human platelets failed to associate with porcine renal endothelial cells. As displayed in 
figure 6.5, the presence of labeled platelets within renal cell populations is confined to the 
CD31-negative cells, suggesting that human platelets do not bind renal endothelial cells 
but do retain the capacity to recognize exposed sub endothelial surface. In contrast, the 
liver endothelial cells (CD31 –positive) demonstrate a strong association with human 
platelets. 
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Figure 6.5: Confocal Imaging of In vitro Uptake. 
	
A WT Liver Endothelial cell line (top) is compared to a WT renal endothelial cell line 
(bottom) procured from the same animal. Right panels include the 488 channel to expose 
human platelet binding. Both primary cell lines were isolated from the same animal and 
subjected to CFSE-labeled human platelets on day 4. Cells were labeled with CD31 [101] 
as to indicate endothelial origin. The results indicate that human platelets associate 
LSECs but not RECs.  Platelet binding in the renal cell fields appears to be contained to 
CD31- sub-endothelial cells. Images are representative of all samples viewed (n= 16 per 
cohort). 
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DISCUSSION  
	
Previous chapters describe new xenoantigen knockout pigs that have reduced the 
antibody barrier for xenotransplantation to the point where the pig-to-human species 
combination has a better crossmatch than the primate-to-human combination.  Data from 
GGTA1-/- -to-primate kidney xenotransplants show that renal xenografts are rejected by a 
mechanism that is characterized by both glomerular IgM and IgG and thrombotic 
microangiopathy (TMA). [165, 166, 169-171] As such, the essential question is whether 
this process of rejection is driven primarily by immune-mediated injury -with exposure of 
pro-coagulant subendothelial surfaces- or is the result of species incompatibility of 
coagulation regulation pathways. [172]   
Incompatibilities of species-specific coagulation regulatory mechanisms have 
frequently been credited with the intravascular thrombosis that produces graft-limiting 
TMA. As previously described by Burlak et al., unmodified porcine livers retain the 
capacity to phagocytose human platelets. [173] The results of the present study confirm 
that this process is measurable within a single-pass model of isolated human platelet 
perfusion.  Although the mechanism of this interaction is not yet fully characterized, 
recent work by Paris et al. has implicated the importance of the asialoglycoprotein 
receptor, produced by the porcine ASGR1 gene. [67, 168] When the ASGR1 gene was 
silenced, porcine livers consumed significantly less human platelets than the WT 
controls. That kidneys do not express the asialoglycoprotein receptor may contribute to 
the differences noted within the present study.  
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  Porcine VonWillebrands factor (vWF) has also been implicated as a possible 
contributor to species-specific coagulation dysfunction as it is able to aggregate human 
platelets in the absence of shear stress. [174]  As displayed in figure 6.1, Robson has 
shown that the porcine O-linked pattern  glycosylation differs from human N-linking 
within the vWF-A1 domain, and may affect the interaction of pig vWF with human 
platelet receptor GPIb. [166, 175] Unlike the asialoglycoprotein receptor, vWF is 
expressed in the kidney, albeit at lower levels compared to other porcine tissue such as 
lung. [176] Our experiments were performed to specifically address the issue of whether 
in the absence of an immunologic injury, human platelets would be aggregated by 
species-incompatibility of coagulation regulatory mechanisms, such as vWF.   
Our results suggest that human platelets respond in a variable fashion to organ-
specific porcine endothelial surfaces. Although the present results display a consistent 
trend towards lower platelet uptake in autologous controls, these differences failed to 
reach statistical significance within renal cohorts. Moreover, it is unlikely that this trend 
represents any biologic relevance given the success of pig-to-primate renal 
transplantation; recently, two pig-to-primate renal transplants have achieved graft 
survival greater than four months without thrombocytopenia. [71, 167]. Unlike the 
kidney, the unmodified porcine liver exhibited a significant ability to consume human 
platelets within this study. Likely owed to its inherently phagocytic nature, the porcine 
liver will require further modification to avoid thrombocytopenia and facilitate successful 
hepatic xenotransplantation.  A number of genetic engineering strategies have been 
employed to limit incompatibilities of species-specific coagulation regulatory 
mechanisms.  The insertion of human transgenes for ecto-ADPase CD39, 
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thrombomodulin, tissue factor pathway inhibitor, and endothelial protein C receptor, have 
all been shown to reduce coagulation of pig organs in primates. [65, 177]   
In light of our data, it seems likely that the graft-limiting intravascular thrombosis 
witnessed in pig-to-primate renal xenotransplatation is more closely the result of 
immunologic injury and not a primary platelet dysregulation.   These findings are not 
unexpected. Foremost, TMA witnessed in renal allograft rejection has long been 
understood as a product of antibody-mediated rejection. [178] TMA is also present in 
other human diseases, such as paroxysmal nocturnal hemoglobinuria, where complement 
activation –the effector of immune-injury- is prevalent. [125]  Within the field of 
xenotransplantation, Cooper et al. have recently shown a link between xenograft 
inflammation and coagulation. [179] In his new paradigm, inflammation precedes 
coagulation, implying that inflammation down-regulation may be independently 
beneficial for xenograft survival.  Similarly, Byrne et al. showed in cardiac xenografts 
that increased immunosuppression, and not increased anticoagulation, was associated 
with improved graft survival. [180]   
The number of circulating xenoreactive antibodies in human serum has been 
greatly reduced with the GGTA1-/- CMAH-/- pig, but there is still room for improvement 
with regards to eliminating xenoantigens.  Byrne et al. recently described porcine 
B4GalNT2 as a gene producing an important xenoantigen in pig-to-primate cardiac 
xenografts. [181]  Estrada et al. then demonstrated the benefit of silencing the B4GalNt2 
gene in both a pig-to-human and pig-to-primate model. [47]  The present data supports 
the notion that these xenoantigen reductions alone may be sufficient to avoid graft-
limiting TMA in a renal xenograft. While the addition of human coagulation regulatory 
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transgenes to donor pigs improves xenograft survival in pig-to-primate model, if the 
xenoreactive titer is low enough these transgenes may be unnecessary for prolongation of 
renal xenograft survival.     
In conclusion, the present study suggests that human platelets respond in a 
variable fashion to organ-specific porcine endothelial surfaces.  Under normothermic 
conditions, human platelets alone are not removed from circulation by exposure to 
porcine renal endothelium, while they are removed by the hepatic endothelium. Kidneys 
possessing genetic modifications currently-relevant to clinical xenotransplantation failed 
to consume human platelets in an isolated single-pass model. In the absence of immune-
mediated endothelial injury, the interaction between human platelets and porcine renal 
endothelium should not represent a barrier to clinical xenotransplantation.  
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 CHAPTER SEVEN: Silencing porcine CMAH and GGTA1 genes 
significantly reduces xenogeneic consumption of human platelets by porcine livers. 
INTRODUCTION  
	
A profound thrombocytopenia limits hepatic xenotransplantation in the pig-to-primate 
model. As exposed by the hepatic control utilized in chapter six, porcine livers also have 
shown the ability to phagocytose human platelets in the absence of immune-mediate 
injury. Recently, inactivation of the porcine ASGR1 gene has been shown to decrease 
this phenomenon. Chapter four and five indicate that inactivating GGTA1 and CMAH 
genes has reduced the antibody-mediated barrier to xenotransplantation; herein I describe 
the effect that these modifications have on xenogeneic consumption of human platelets in 
the absence of immune-mediated graft injury. 
As discussed in the first chapter, the most pressing issue affecting patients 
awaiting transplant is a growing dearth of available allografts. While peak transplanted 
volumes for all solid organs has plateaued, each year the number of patients added to 
solid-organ wait lists increases.[148] As recently stated by Salomon et al., from the 
AST/ASTS workshop on increasing liver donation:  “our current system of organ 
donation is not meeting the growing demand”. [182] Xenotransplantation of genetically 
modified porcine organs is now positioned to be a clinically-viable answer to this 
growing problem. The advances in genetic engineering presented in chapter two have 
rapidly increased the pace at which model organs may be created and tested. [115]  
Recently, as described in chapter four, a triple knockout model has reduced human 
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antibody-dependent cytotoxicity below the threshold at which acute antibody-mediated 
rejection (AMR) would not be expected. [27] It is from this position of immunologic 
equivalence, that it is now important to examine organ-specific barriers to clinical 
xenotransplantation. While the previous chapter suggests that porcine renal endothelium 
will be inert to human platelets in the absence of concurrent immunologic insult, the 
consumption of human platelets by the wild-type livers included within that analysis 
suggests that human platelets respond in a variable fashion to organ-specific porcine 
endothelial surfaces. 
The xenogenic consumption of platelets by porcine livers is well-precedented 
phenomenon; the use of porcine livers for xenotransplantation is limited by a dramatic 
thrombocytopenia when studied in a pig-to-primate model. [183] As described by Burlak 
et al., [173] porcine sinusoidal endothelial cells (LSEC) and Kupffer cells (KC) also 
remove human platelets from circulation in the absence of immunologic injury or sheer-
stress activation. Recently, gene silencing has been used to limit this thrombocytopenia. 
As described by Paris et al., [67] removing the asialoglycoprotein receptor 1 protein from 
the porcine livers significantly reduces the amount of human platelet uptake. Although 
carbohydrate reductions have proved essential to limiting AMR in a pig-to-human model, 
little attention has been afforded to the effect that these modifications may have on 
hepatic platelet consumption. Silencing of the GGTA1 gene, which facilitates cell surface 
expression of the Galα(1,3)Gal  (αGal) xenoantigen, and the CMAH gene which allows 
expression of the N-Glycolylneuraminic acid (Neu5Gc) xenoantigen may help avoid 
early xenogeneic AMR;[38] it is therefore important to understand the effect that these 
modifications have on the human thromboregulatory system. Herein we describe the 
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effect that silencing the porcine GGTA1 and CMAH genes has on the consumption of 
human platelets by a porcine liver.  
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MATERIALS AND METHODS  
 
Genetically modified pigs 
The GGTA1-/-, GGTA1-/-CMAH-/- and ASGR1-/- pigs used in this study have been 
described previously.[24, 67] Briefly, the same parental background was used across all 
animals to limit variability from external loci.  GGTA1 and CMAH gene silencing was 
accomplished by CRISPR/Cas9-directed mutagenesis as described by Li et al. [24] 
ASGR1 silencing was effected by TALEN- directed mutagenesis as described by Paris et 
al. [67] [100] The Institutional Biosafety and Institutional Animal Care and Use 
Committee at Indiana University School of Medicine approved the use of animals in this 
research.    
 
Platelet Isolation and Staining 
One unit of expired human platelets was purchased from a local blood bank. The platelets 
were centrifuged (5 minutes at 5,000xg). The pellet was resuspended in PBS/ACD 50:1 
and washed twice. 2x1011 platelets were obtained by count on hemocytometer, of which 
25 percent were labeled with carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, 
Grand Island, NY) as described. [173] Both labeled and unlabeled platelets were added to 
a total of 1L modified Krebs solution 2.0g/L D-glucose, 0.141 g/L MgSO4, 0.16 g/L 
KH2PO4, 0.35 g/L KCl, 6.9 g/L NaCl, 2.10 g/L NaHCO3, 0.37g/L CaCl2, 2.38 g/L 
HEPES, 1U/mL Heparin (Sagent Pharmaceuticals, Schaumburg, IL) pH 7.2-7.4 and then 
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perfused through a Capiox BT05 bubble trap (Terumo Medical, Tokyo, Japan) to remove 
aggregated platelets prior to perfusion. Platelets were again counted to account for 
platelet loss and resuspended at a concentration of 1x1010/L in modified Krebs solution. 
A total of 10L of platelet suspension was prepared and was warmed to 37 °C until 
perfusion. 
 
Perfusion of Livers 
Livers were procured from genetically modified animals and flushed at time of 
procurement with HTK solution (Essential Pharmaceuticals, Ewing, NJ, USA).  Organs 
were removed from cold preservation within 2 hours and cannulated to achieve definitive 
control of the portal vein, hepatic artery and suprahepatic inferior vena cava and were 
warmed to a controlled temperature range of 35-37 °C by perfusion with warmed Kreb’s 
solution. Livers were perfused in an oxygenated and pulsatile circuit as previously 
described. [67] For the single-pass model, sampling occurred simultaneously from the 
hepatic artery, portal vein and suprahepatic inferior vena cava; samples were collected 
every 30 seconds for 10 minutes.  A sample from the vena cava port was collected at time 
0 to calculate a background fluorescence which was subtracted from all samples.  For the 
continuous-pass model, a time zero sample of platelets was obtained prior to the 
introduction of platelets, and samples were taken from a central reservoir at reported time 
points and immediately fixed 1:1 in 10 percent formalin solution prior to counting.  
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Measuring Xenogeneic Human Platelet Consumption  
For the continuous-pass model, each of the time point samples were counted using a 
hemocytometer and total available platelets in the perfusion system were calculated. 
These values were compared to input platelet amounts and percent remaining available 
platelets were calculated. Results were subjected to analysis by ANOVA with repeated 
measures and Tukey’s post test to determine significance. Samples obtained from single-
pass hepatic perfusions were analyzed by measuring the fluorescence (Ex: 485, Em: 525) 
of 200uL perfusate loaded into 96 well micro clear plates (Greiner Bio One, Monroe, NC, 
USA) on a Spectramax M2 plate reader (Molecular Devices Corp., Sunnyvale, CA, 
USA). Percent maximum fluorescence was calculated by comparing individual time 
points to input fluorescence. Percent maximum values were analyzed on Prism software 
(Graphpad Software Inc., La Jolla, CA). Inclusion criteria for statistical analysis required 
that arterial and portal vein fluorescence reached at least 90% of input fluorescence to 
suggest adequate circulation of labeled platelets through the system. Comparison of 
platelet quantities in the perfusate were made once the platelet levels had plateaued 
indicating that the system had reached a steady state.  Statistical significance was 
determined by unpaired t-test of percent fluorescence values obtained after inclusion 
criteria were met. 
 
Staining and Confocal Microscopy 
For histologic analysis by in vitro assay, primary WT, GGTA1-/- , ASGR1-/- and CMAH-/-
GGTA1-/- LSEC lines were isolated as previously described. [173]  Cells were cultured 
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for 4 days post isolation at 37 °C and 5% CO2 in clear-bottomed cell culture-treated 
microscopy slide wells (100, 000 cells/well initial concentration). Fresh human platelets 
were isolated from a healthy donor and labeled with carboxyfluorescein succinimidyl 
ester (CFSE) as described above.  Four million CFSE-labeled platelets were added to 
experimental wells containing primary endothelial cells and media. Slides were incubated 
with platelets for 60 minutes. Duplicate wells for each group were washed with 150 µL of 
PBS three times then fixed with 50 µL of 4% paraformaldehyde–PBS solution for 
20 min. To facilitate immunohistochemical visualization, and confirmation of platelet 
deposition within ex vivo platelet-perfused livers, punch biopsies were obtained at the 
conclusion of perfusions, sectioned at 4um and then fixed with 50 µL of 4% 
paraformaldehyde–PBS solution for 20 min. Cells and tissues were stained with goat 
anti-Pig CD31 1:100 (R and D systems, Minneapolis, MN) to visualize the endothelial 
surface, followed by three PBS washes and bovine anti-goat IgG DyLight 649 (Jackson 
Immuno Research Laboratories Inc., West Grove, PA). Slides were incubated with 
secondary antibody for approximately 1 h and then washed three times with PBS. DAPI 
(Invitrogen, Grand Island, NY) was added to all slides for 1 min as a nuclear stain 
followed by two PBS washes. Slides were mounted in ProLong Gold (Invitrogen, Grand 
Island, NY). Confocal microscopy was performed using an Olympus FV1000 (Olympus 
America Inc., Center Valley, PA, USA).  
  
	138 
RESULTS  
 
Analysis of in Vitro Human Platelet Uptake  
CFSE-labeled human platelets associate less with isolated porcine liver endothelial cells 
from the GGTA1-/-CMAH-/- background compared to GGTA1-/- and WT cells. The ratio 
of human platelets [19] bound by liver endothelial cells [101] was measured by 
colocalization of platelet per CD31+ cell for all 16 fields viewed per cohort. The median 
LSECs per field was 58 and was not significantly different across cohorts (p=0.32).  
When subjected to statistical analysis by ANOVA with Tukey’s multiple comparison test, 
GGTA1-/-CMAH-/- LSECs bound significantly fewer human platelets when compared to 
GGTA1-/- (0.13 vs 0.34 platelets per LSEC p=0.002, n=16) and WT (0.13 vs 0.37 
platelets per LSEC p=0.002 n=16) cells; ASGR1-/- LSECs exhibited significantly less 
platelet binding than GGTA1-/-  (0.17 vs 0.34 platelets per LSEC p=0.013, n=16) and WT 
(0.17 vs 0.37 platelets per LSEC p=0.009, n=16) cells. Although GGTA1-/-CMAH-/- 
LSECs appeared to be associated with fewer human platelets than ASGR1-/- LSECs, the 
difference failed to reach statistical significance (0.13 vs 0.17 platelets per LSEC p= 0.8, 
n=16). Cells from GGTA1-/- and wild type livers exhibited similar levels of platelet 
retention (0.34 vs 0.37 platelets per LSEC p=0.99, n=16). The images in figure 7.1 are 
representative of all images captured (n= 16 for each cohort). 
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Figure 7.1: Human platelet accumulation by GGTA1-/-CMAH-/-, GGTA1-/-, ASGR1-/- 
and WT liver sinusoidal endothelial cells in vitro.  
	
Primary WT, GGTA1-/-, ASGR1-/- and CMAH-/-GGTA1-/- LSEC lines were isolated and 
cultured for 4 days. Human platelets were isolated from a healthy donor and labeled with 
carboxyfluorescein succinimidyl ester (CFSE). Labeled Platelets [19] were added to 
experimental wells containing primary endothelial cells. Cells were stained with anti-Pig 
CD31 [101] to visualize the endothelial surface; and DAPI [75] was added to all slides as 
a nuclear stain. Confocal microscopy was performed using an Olympus FV1000. The 
relationships between human platelets and GGTA1-/-CMAH-/- or GGTA1-/- livers seen in 
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the ex vivo perfusion model was upheld by in vitro analysis. Based on colocalization 
analysis, CFSE-labeled human platelets associated less with porcine liver endothelial 
cells from the GGTA1-/-CMAH-/- background compared to WT (p=0.002) and GGTA1-/- 
(p=0.002) cells; ASGR1-/- LSECs exhibited significantly less platelet binding than 
GGTA1-/-  (p=0.013) and WT (p=0.009) cells. Although GGTA1-/-CMAH-/- LSECs 
appeared to associate fewer human platelets than ASGR1-/- LSECs, the difference failed 
to reach statistical significance (p= 0.8). Figure is representative of all images captured 
(n= 16 for each cohort). 
 
Analysis of Ex Vivo Perfusion with Human Platelets 
Because of the reduced interaction of human platelets with GGTA1-/-CMAH-/- porcine 
liver sinusoidal endothelial cells, perfusion studies were performed to determine if the 
removal of human platelets from a perfusion circuit was also minimized.  In a 
continuous-pass model of platelet uptake, GGTA1-/-CMAH-/- livers consumed fewer 
platelets than GGTA1-/- (p<0.0001) and WT (p<0.0001) livers at every time point (Figure 
7.2). We have previously demonstrated that eliminating the asialoglycoprotein receptor 
from pig livers reduced human platelet consumption when compared to WT; [67] when 
compared within this analysis, these findings were confirmed (p<0.0001). Although a 
trend towards lower platelet uptake was noticed when comparing GGTA1-/-CMAH-/- to 
ASGR1-/- livers, the difference failed to reach statistical significance at two of the time 
points within this model (p<0.161).  Representative immunochemical histology obtained 
post continuous pass perfusion is shown in figure 7.2B and confirms that the loss of 
platelets through the system is a function of hepatic deposition.  
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Figure 7.2: A Continuous-pass model for the xenogenic consumption of human 
platelets by modified porcine livers. 
	
(A) In a continuous-pass model of platelet uptake, both GGTA1-/- CMAH-/- and ASGR1-/- 
livers consumed fewer platelets than GGTA1-/- or WT livers (p<0.0001 for all 
comparisons). Platelet disappearance from the system was less at each measured time 
point after time zero.  Although a trend towards lower platelet uptake was noticed when 
comparing GGTA1-/-CMAH-/- to ASGR1-/- livers, the difference failed to reach statistical 
significance at two of the time points within this model (p<0.161). (GGTA1-/- n=2, 
GGTA1-/- CMAH-/- n=3, WT n=3 and ASGR1-/- n=3). The ASGR1-/- data was published 
previously and used here with permission. [67] (B) Representative immunochemical 
histology obtained from post continuous pass perfusion hepatic tissue sectioning is shown 
and confirms that the loss of platelets through the system is a function of hepatic 
deposition. Labeled Platelets [19] were added to experimental wells containing primary 
endothelial cells. Cells were stained with anti-Pig CD31 [101] to visualize the endothelial 
surface. Confocal microscopy was performed using an Olympus FV1000. Images are 
representative of all samples viewed (n= 6 for each perfusion). 
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To better characterize the difference between GGTA1-/-CMAH-/- livers and 
ASGR1-/- livers, we sought to increase the sensitivity of our perfusion model.  Though 
continuous pass circuits are sufficient for demonstrating large differences in platelet 
uptake, it was insufficient to reliably measure more subtle differences.  Consequently, we 
developed a “single pass” perfusion circuit to examine the loss of platelets following 
transit through the organ a single time.  Serial samples were collected until the input 
(artery and portal vein,) and the output (vena cava) reached a plateau, indicating steady 
state had been reached (Figure 7.3). After plateau phase was achieved, data from time 
points 390, 420 and 450 seconds were averaged (Figure 7.3D); suprahepatic inferior vena 
cava fluorescence reached 95.4%  (SEM=0.590) of initial sample fluorescence for 
GGTA1-/- CMAH-/- livers compared to 83.9% (SEM=0.513) in ASGR1-/- livers during 
steady-state. (P= 0.001, GGTA1-/- CMAH-/- n=3, ASGR1-/- n= 4) 
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Figure 7.3: A single-pass model of human platelet uptake for GGTA1-/- CMAH-/- 
and ASGR1-/- livers.  
	
To further characterize a trend noted within a continuous pass model, livers of a GGTA1-
/- CMAH-/- background were compared to ASGR1-/- livers in a more sensitive single pass 
model. Livers of a GGTA1-/- CMAH-/- background consumed significantly fewer platelets 
than ASGR1-/- livers in a single-pass model of human platelet uptake. After the addition 
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of CFSE-labeled human platelets into the circuit, samples were obtained simultaneously 
from the hepatic artery (A), portal vein (B), and suprahepatic inferior vena cava (C), over 
time and measured for fluorescence. Each sample was measured against the pre-perfusion 
fluorescence measurement to achieve a percent input fluorescence value.  (D) After 
plateau phase was achieved, data from time points 390, 420 and 450 seconds were 
averaged; suprahepatic inferior vena cava fluorescence reached 95.4%  (SEM=0.590) of 
initial sample fluorescence for GGTA1-/- CMAH-/- livers compared to 83.9% 
(SEM=0.513) in ASGR1-/- livers during steady-state. (P= 0.001, GGTA1-/- CMAH-/- n=3, 
ASGR1-/- n= 4) Representative immunochemical histology obtained post single pass 
perfusion is shown at figure-right and confirms that the loss of platelets through the 
system is a function of hepatic deposition. 
  
	145 
DISCUSSION  
 
With the recent success of new knockout models described in previous chapters, the 
antibody barrier to clinical application has effectively been crossed. [27] Prior to human 
trials, it is important to understand the physiologic compatibility of these organs with the 
human thromboregulatory system. Unlike renal xenotransplantation, Pig-to-primate and 
pig-to-human models of hepatic xenotransplantation are challenged by early 
thrombocytopenia. Although activated human platelets will interact with all porcine 
endothelial cells, the porcine liver is uniquely capable of removing unactivated platelets 
from circulation. [173, 184] Though the mechanism remains poorly understood, it 
appears that porcine asialoglycoprotein receptor and Von Willebrand factor may 
contribute to this interaction. [166, 168, 175, 185] Recent efforts to reduce xenogeneic 
thrombocytopenia in a pig-to-primate model have also exposed the importance of 
limiting immune-mediated graft injury. [186, 187] Judicious immunosuppression has 
prevented thrombocytopenia following pig-to-primate xenotransplantation of the porcine 
heart and kidney. [15, 188] Given this information, it is possible that a combination of 
immunosuppression and the reduced antigenicity of newer knockout porcine donors alone 
may facilitate success for renal or cardiac xenografts. Owed to the inherently phagocytic 
tendency of the liver, further modifications will be necessary to avoid thrombocytopenia 
with hepatic xenografts.  
The porcine ASGR1 gene produces the asialoglycoprotein receptor, which is 
known to bind and clear human platelets. Paris et al. previously demonstrated that 
ASGR1-/- livers consume fewer human platelets than WT livers, making them a more 
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appropriate comparison for the present study. [67] GGTA1 and CMAH genes produce 
carbohydrates on the porcine cell surface; humans and primates have inactivated these 
genes over the course of evolution and therefore carry pre-formed antibodies against the 
products. Silencing these carbohydrate genes results in a favorable crossmatch against 
human sera, and therefore will be necessary for clinical application of pig-to-human 
xenotransplantation. [38] Surprisingly, these same modifications that have reduced the 
xenoantigen barrier also reduce the consumption of human platelets by the porcine liver, 
even in the absence of immune-mediated injury.  Elimination of the CMAH gene appears 
to provide the majority of protection from platelet consumption.   
Though the relationship between carbohydrate profiles and hepatic platelet uptake 
is still being defined, the ability of carbohydrates to affect hepatic recognition and 
transport has been recognized for over 30 years. [189] More recently, hepatic lectins and 
surface carbohydrates have been implicated in the process of hepatic platelet 
consumption.  [190-192] Although the specific role of Neu5Gc (CMAH gene product) 
remains unknown, its induced expression on human atherosclerotic plaques [141] and 
cancer cells [193] in vivo suggests a link between altered N-glycan structure and human 
platelet adhesion. It is plausible that the induced expression of Neu5Gc in human solid-
organ malignancies is partially responsible for the tumor-induced prothrombotic state, 
and that Neu5Gc-mediated aggregation is responsible for the human platelet’s supportive 
role in tumor metastasis. [194] 
Humanizing the porcine carbohydrate profile significantly reduces xenogeneic 
consumption of human platelets by the porcine liver. Simultaneous silencing of the 
GGTA1 and CMAH genes outperformed both GGTA1-/- and ASGR1-/- livers with respect 
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to reduction in human platelet uptake. It is likely that a combination of carbohydrate and 
receptor protein knockout strategies will limit the xenogeneic thrombocytopenia 
associated with pig-to-human hepatic transplantation and facilitate clinical application.  
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CHAPTER EIGHT: Conserved FcRN-albumin interactions across species: 
implications for porcine-to-human renal xenotransplantation. 
INTRODUCTION  
	
The previous two chapter have described significant improvements in our understanding 
of thromboregulatory barrier to porcine-to-human xenotransplantation. The pivotal gene-
modifications described in chapter four have now made clinical application an 
immunologic possibility; they also appear to limit physiologic barriers at the endothelial 
level. One of the salient findings described within chapters 6-7, is that human platelets 
react to porcine endothelium in an organ-specific manner. Although it is likely that more 
genome modifications will be needed to avoid xenogenic consumption of human platelets 
by porcine livers, porcine-to-human renal transplantation appears unaffected by this 
problem. For this reason, it is appropriate to appraise porcine kidneys as the first suitable 
xenograft for human trials.  
Renal transplant currently represents the best available treatment for end-stage 
renal diseases. Unfortunately, the application of this life-saving treatment is severely 
limited by a growing shortage of available allografts for transplant. Despite considerable 
effort to increase availability of allografts for transplant, increases in organ supply 
continue to be outpaced by a growing number of patients awaiting renal transplant.  
Although xenotransplantaton has been studied for multiple decades as a potential answer 
to this problem, only recently has it reached potential clinical relevance. Specifically, the 
carbohydrate-modified model of porcine-to-human xenotransplantation described in 
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chapter four now exhibits very low levels of human antibody binding.[195] Because the 
human antibody response to genetically modified porcine cells is now at standards 
established by matched allograft allocation, clinical application is within reason.  
With the salient barrier of hyperacute humoral xenogeneic response 
circumvented, it is now increasingly important to consider potential physiologic barriers 
to clinical application at an organ-specific level. Although a clinical trial is needed, 
considerable in vivo and ex vivo evidence indicates that porcine kidneys will perform 
appropriately when transplanted into humans. Despite the evidence to support 
physiologic compatibility, the potential for graft-induced proteinuria has remained 
contentious.  
Renal pathologies defined by macromolecule loss, such as serum albumin, have 
traditionally been associated with damage at the glomerular filtration barrier.  This 
paradigm explains the flagrant proteinuria encountered during complement-mediated 
damage to the vascular endothelium that defines immune-mediated allograft rejection. 
Because historic models of porcine-to-primate renal xenotransplantation were afflicted by 
immunologic incompatibility and early graft loss, it remained unclear whether observed 
proteinuria was indicative of a primary molecular incompatibility or was simply 
derivative to immune-mediated damage.  
Recently, it has been discovered that serum albumin is a renal filtrate; serum 
proteostasis is dependent on post-glomerulus albumin absorption.[196] In particular, the 
neonatal Fc receptor (FcRn) has been identified as a primary driver of renal proximal 
tubule albumin absorption. (Figure 8.1)  
	150 
 
 
 
Figure 8.1: FCRN mediated albumin absorption at the proximal tubule. 
	
Recent evidence supports the fact that albumin is freely filtered across bowman’s 
capsule. To maintain homeostatic serum concentrations, albumin is the absorbed by the 
proximal tubule cell. The FcRN-albumin interaction is essential to this process.  
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FcRn sequence is highly conserved across species, making physiologic compatibility 
across species very likely (Figure 8.2), despite this level of homology the interaction 
warrants dedicated investigation prior to human clinical trials. The object of the present 
work is to examine the porcine kidney’s potential to process human protein in the 
absence of immunologic injury. We describe the interaction between human albumin and 
the porcine kidney at a molecular, cellular and organ level, finally we examine 
proteinuria in a modern in vivo model of renal xenotransplantation.  
 
Figure 8.2: FcRn receptor sequence is highly conserved across species.  
	
The porcine FcRn cDNA is 1,577 bp in length (GenBank Accession Number: 
AY135635) and contains a 1,077 bp open reading frame [136] encoding a 356-amino 
acid polypeptide. The 3′ end of the sequence contains a poly(A) stretch, preceded by a 
putative polyadenylation signal AATAAA (nucleotides 1523–1529). Blast analysis 
revealed that the mRNA sequence of the porcine FcRn gene has 79.4%, 66.3% and 
83.9% nucleotide identity with the corresponding gene in human, and rhesus respectively. 
Comparison of predicted porcine FcRn amino acid sequence with that of human, mouse, 
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rat and cattle indicated an identity of 77.1%, 66.3%, 64.2% and 83.9%, respectively. The 
complete porcine FcRn genomic DNA sequence spans 8,900 bp (GenBank accession 
number: HQ026019) and it consists of 5 introns separating 6 exons. The intron/exon 
organization of porcine (5 introns and 6 exons) is identical with that of the human and 
rhesus FcRn gene. Although these sequences may predict conserved functional FcRn-
albumin interactions across species, specific inquiry is warranted at a molecular and 
cellular level.  
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MATERIALS AND METHODS  
 
Intravital 2-photon microscopy 
Although urinary loss of serum macromocules is traditionally associated with insult to 
cellular integrity at the glomerular level, recent evidence supports the fact that albumin is 
universally filtered in the normal physiologic state; resorption of filtered albumin by the 
proximal tubule epithelial cells is essential for maintaining serum levels albumin. 
Intravital 2-photon microcopy has been instrumental in the elucidation of this 
phenomenon; by visualizing labeled serum albumin perfused through kidneys in real 
time, its presence in the glomerular filtrate may be appreciated under physiologic 
conditions.[197] Though this process has been identified across species including rat, 
mouse, and human, this is the first reported use of dual photon microcopy to assess the 
porcine kidney.  
 
Fluorescent labeling of human albumin 
100mg of human serum albumin (HSA) (Albumin Bioscience, Huntsville AL, USA) was 
sollulabized in 6.667ml of 100 mM Sodium Bicarbonate ph 9.0; final concentration of 
15mg/ml. 200ul of high quality anhydrous Dimethyl Formaide (DMF) was added to a 10 
mg vial of Texas Red Sulfonyl Chloride (TRSC) (ThermoFisher Scientific, Waltham 
MA, USA) and this solution was incubated with 50ml of solubilized HSA at 4degrees for 
one hour. The solution of labeled HSA was then dialyzed to remove unconjugated TRSC.  
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Porcine kidney preparation and microcopy 
Wild type porcine kidneys were obtained through surgical procurement as previously 
described.[198] All animals used were approved for use by the Institutional Animal Care 
and Use Committee at Indiana University. After procurement, kidneys were immediately 
pumped in a pulsatile perfusion circuit at 35 degrees as previously described. One Liter 
of autologous whole blood obtained from donor animal diluted 1:1 with Tyrode’s 
solution (Sigma-Aldrich, St. Louis, MO, USA) was used for perfusate. TRSC-labeled 
human albumin was added to the circuit to achieve physiologic concentration of human 
albumin. A window through the fibrous renal capsule was removed to allow for better 
microcopy resolution. An Olympus FV1000 2-photon confocal microscope was fitted 
with an inverted microscope stage and was used to collect images. The gallium-arsenide 
phosphide non-descanned photodetectors were set to 750 to collect green emissions, and 
625 to collect red emissions.  
 
In vitro proximal tubule cell analysis 
Because recent evidence supports both the filtration and resorption of serum albumin, we 
sought to obtain a more precise measurement of renal proximal tubule handling of 
filtered albumin in the porcine-to-human model of renal xenotransplantation. To this end 
we obtained porcine and human proximal tubule cell lines. The porcine ‘LLCPK1’ 
proximal tubule cell line as described by Nielsen et al.[199] was purchased from 
American Type Culture Collection (ATCC, Manassas VA, USA). The ‘TH1’ human 
renal proximal tubule cell line was purchased from Kerafast (Boston, MA USA). Cell 
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lines were maintained in modified endothelial cell line Medium 199+ 2mM Glutamine + 
10% Fetal Bovine Serum (Sigma-Aldrich, St. Louis, MO, USA) at 37degrees in 5% C02. 
Cultures were seeded at 2e6cells/cm2 and grown to confluence. Incubation with TRSC-
labeled human albumin at confluence in a 96-well optical chamber at a concentration of 
6.47uM for 30 mins at 37deg. All chambers were then washed in triplicate with 
phosphate buffered solution (PBS) to remove unabsorbed albumin. Albumin uptake was 
read on a Spetramax M2 fluoresce plate reader (Molecular Devices Corp., Sunnyvale, 
CA, USA). Nine consecutive readings were obtained for each sample and relative 
fluorescence values [121] were recorded as median 647 emissions. For duplicate analysis 
of uptake, cells were then trypsinized using 0.25 trypsin/EDTA, and read in median 
fluorescence intensity (MFI) by flow cytometry using an Accuri C6 flow cytometer 
(Accuri, Ann Arbor, MI, USA). All experiments were performed in triplicate. 
 
Kinetics analysis of FcRN-Albumin interaction 
With an established model to assess cross-species albumin-FcRN interaction at the 
cellular level, we sought to better understand the this relationship at the molecular level. 
The neonatal FcRn molecule is known to be responsible for binding albumin. The FcRN 
receptor is highly conserved across species, and although previously published data 
supports the fidelity of the albumin-FcRn interaction across several species, this is the 
first report to specifically query the interaction between human albumin and porcine 
FcRn. Human soluble FcRN Binding experiments were performed on Biacore 3000 at 
25°C.  The ligand pFcRn~his, huFcRn~GST and pFcRn~GST were directly immobilized 
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to 3 different flow cells of the CM5 chip by EDC/NHS amine coupling method as per GE 
instruction. The un-occupied sites were blocked with 1M ethanol amine. Flow cell1 was   
used as blank for reference subtraction.  The analyte as indicated was flowed over the 
chip at variable concentrations.  Binding of analyte to the ligand was monitored in real 
time.  KD was determined from the observed on rate (ka) and off rate (kd).  Scouting 
Analysis was performed at single analyte concentration (1000nM) to confirm yes / no 
binding. Full kinetic analysis was performed at a highest concentration as indicated, 
followed by 2-fold serial dilution. Chi square (c2) analysis was carried out between the 
actual Sensorgram (colored line) and the sensorgram generated from the BIAnalysis 
software (black line) to determine the accuracy of the analysis. c2 value within 1- 2 is 
considered significant (accurate) and below 1 is highly significant (highly accurate). 
 
In vivo evaluation of proteinuria   
Genetically modified pigs were created by CRISPR/Cas9 mutagenesis and somatic cell 
nuclear transfer as previously described by Li et al.[24] Animals for the present analysis 
were of a GGTA1-/- B4GalNt2-/- background. Pigs were grown to physiologic maturity 
at which point kidneys were removed under general anesthetic. All use of animals was 
approved under the Emory University and Indiana University Institutional Animal Care 
and Use Committee. Kidneys were transplanted into rhesus macaque monkeys after 
bilateral recipient nephrectomy. Immunosuppression protocol described by 
Higginbotham et al. was used.[71] Proteinuria was measured by urine analysis over time 
after transplant.  
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RESULTS  
	
Texas Red Sulfonyl Chloride-labeled human albumin marker established a visualizable 
marker of renal protein handling. Dual-photon intravital microcopy was able to penetrate 
decapsulated porcine kidneys to the level of the porcine glomerulus. This process was 
successful in illustrating the presence of human albumin as a renal filtrate in the absence 
of immune-mediated injury. (Figure 8.3A).  
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Figure 8.3: Human albumin in the porcine kidney: filtered and absorbed.  
	
Recently it has been discovered in human, mouse and rat models that albumin passes the 
glomerular barrier in physiologic state. Here we utilized dual photon microcopy and 
fluorescent labeled human albumin to establish that human albumin is also a part of the 
porcine renal filtrate under physiologic conditions. Furthermore, when studied on a 
cellular level porcine proximal tubule cells absorb human albumin in equivalent amounts 
to human proximal tubule cells. This suggests a conserved physiology of renal albumin 
trafficking across the human and porcine species. 
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As has recently been described in mouse, rat and human models, albumin is 
filtered at the porcine glomerulus. The porcine renal proximal tubule cell is capable of 
absorbing human albumin at equivalent efficiency as the human renal proximal tubule 
cells. Once filtered, albumin enters the proximal tubule. Here we established that porcine 
proximal tubule cells absorb human albumin at levels equivalent to human proximal 
tubule cells. (Figure 8.3B) At the molecular level FcRn is known to mediate albumin 
trafficking. To assess the protein-protein interaction of albumin and FcRn across species, 
we established a surface plasmon resonance analysis. We found that the molecular 
interaction between FcRN and albumin is conserved across the porcine and human 
proteomes. FcRn binds human albumin with the same affinity it does autologous porcine 
albumin; KD values of 7.22e-7 vs 3.92e-7 respectively (p= 0.21). (Figure 8.4). 
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Figure 8.4: Surface plasmon resonance analysis of FcRn-albumin kinetics. 
	
FcRn functions in the renal cortex as an albumin receptor, as such it is essential in 
maintain serum proteostasis. When the protein-protein interaction between albumin and 
FcRn across species we found that porcine FcRn binds human albumin with the same 
affinity as it does autologous porcine albumin, suggesting that that there is no inherent 
molecular incompatibility that would promote renal albumin loss in porcine-to-human 
renal transplantation.  
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  Prior to human clinical trials of renal xenotransplantation, in vivo study has relied 
on porcine-to-primate models. Although older pig-to-primate models raised the concerns 
of post-transplant proteinuria, this problem is not appreciated in the absence of graft 
rejection. Because the CMAH gene product (Neu5Gc) discussed in chapters 2-4 is 
expressed in the rhesus monkey, its relevance as a xenoantigen is limited to the porcine-
to-human model; GGTA1 and B4GalNt2 genes are the most significant glycan drivers of 
primate-anti-porcine humoral response.  Using a GGTA1-/- B4GalNt2-/- porcine kidney 
for transplant after bilateral native renal ligation, coupled with conventional immune 
suppression, graft function has been sustained for greater than one year. Over this time 
period no proteinuria has been appreciated.  (Figure 8.5).   
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Figure 8.5: Urine protein over time in a pig-to-primate model of 
xenotransplantation. 
	
A GGTA1-/- B4GalNt2-/- Pig was created by methods described within chapter three. 
This pig was grown to maturity, serving as renal xenograft donor for a life sustaining 
xeno-renal transplant into a rhesus macaque. Bilateral native renal vascular ligation was 
performed at the time of transplant. Immunosuppressive regime was used as described by 
Higginbotham et al. [71]. Urine protein was measured over time measure the porcine 
kidney’s ability to facilitate primate proteostasis. The peak observed within the first two 
weeks after transplant is attributable to reperfusion injury, and is universally appreciated 
in human allotransplantation. Urine protein remained negligible in this model thereafter.   
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Although xenotransplantation of porcine kidneys will require a human clinical 
trial to definitively assess clinical relevance, information gained from non-human primate 
recipients remains helpful. To date, a considerable body of in vivo and ex vivo data 
suggests that porcine kidneys will function well in humans. Within these studies, 
proteinuria has arisen as the salient remaining physiologic question. Here we show that 
when the immunologic barrier of humoral xenograft rejection is removed, proteinuria is 
not encountered.  
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DISCUSSION  
 
A hallmark of many renal disease states is the urinary loss of essential macromolecules 
like serum albumin. Traditionally this has been associated with insult to the filtration 
barrier. In renal transplantation, the vascular endothelium comprises the first site of 
complement-mediated humoral graft injury. The in vivo study of porcine renal xenografts 
has relied on non-human primate recipients. Unfortunately, previous models of porcine-
to-primate xenotransplantation were affected by significant humoral rejection; in this 
context reliable study of long-term serum proteostasis has been challenging.  Although 
hypoalbuminemia and proteinuria have been reported in baboon and cyomologous 
monkey recipients of porcine kidneys, authours have avoided making definitive 
conclusion regarding the etiology of this phenomenon. Aware of the immunologic 
shortcomings to previous pig-to-primate models, they have only concluded that this 
witnessed proteinuria “may be indicative of renal injury after xenotransplantation or 
abnormal handling by the pig kidney of primate plasma proteins.” Herein we report the 
first series of experiments that specifically query the physiology of renal protein 
interactions across porcine-primate lines.  
Serum albumin is the salient driver of clinically relevant proteinuria post-
transplant; as the most abundant serum macromolecule, it is the primary driver of serum 
oncotic pressure. As such we felt that the relationship between human serum albumin and 
the porcine kidney deserved privileged attention. The results of the present study answer 
a lingering debate as to whether the hypoalbuminuria noted in some previous porcine-to-
primate models represented anything more than immune-mediated graft injury. It appears 
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that in the absence of acute humoral xenograft rejection (AHXR), porcine kidneys will be 
capable of maintaining physiologic serum albumin levels.  
Although xenotransplantation of porcine kidneys will require a human clinical 
trial to definitively assess clinical relevance, information gained from non-human primate 
recipients remains helpful. To date, a considerable body of in vivo and ex vivo data 
suggests that porcine kidneys will function well in humans. Within these studies, 
proteinuria has arisen as the salient remaining physiologic question.  Proteinuria after 
renal allotransplatation is routine; it is associated with transient glomerular reperfusion 
injury. Importantly, extensive human data has shown that continuous but not intermittent 
proteinuria is associated with diminished graft survival. The results of the present study 
show that when the barrier of acute humoral xenograft rejection is removed, porcine 
kidneys are capable of maintaining serum proteostasis for greater than one-year post 
transplantation. Proteinuria should no longer be considered a physiologic barrier to 
clinical application porcine-to-human renal xenotransplantation.  
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CLOSING REMARKS 
 
Dr. Thomas Starzl, who passed away in the month before this thesis was presented 
publically, pioneered the success of human allotransplantation through a meticulous 
study of both operative technique and immune-modification. Though allotransplantation 
has now become a critical component of modern medical care for patients with end-
stage-organ dysfunction, the practice remains severely limited by a growing shortage of 
available allografts. As discussed in chapter one, approximately 14 patients die each day 
in the United States while waiting for a renal allograft. However the true burden of 
world-wide organ shortages likely escapes objective metrics. Faced with a growing 
dearth of available solid organs for transplant, indications for transplantation are limited. 
The current allocation process favors patients most-likely to receive durable benefit from 
transplantation. By including things like age, psychological assessment, concurrent 
malignancy and even financial ability to cover surveillance costs, current transplant wait-
listing excludes many who need life-saving organs; this process of organ-rationing 
translates directly into death without transplant for an unquantifiable number. Finally, as 
is the case in many arenas of gross supply-demand inequality, a dark undercurrent of 
social injustice ebbs outside the borders of regulation. Although beyond the scope of the 
present discussion, the monetization of human organs by organ-trafficking is a world-
wide problem, with an arguably underappreciated imprint on global human rights. 
Dr. Starzl himself anticipated many of these problems, and even in the burgeoning 
era of transplantation when solid organ wait-times were minimal, he dreamed of 
xenotransplantation as a potential answer to today’s problem. Dr Starzl was an early 
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mentor to Dr. A. Joseph Tector and today I am in great debt to the constant mentorship of 
Dr Tector, who has dedicated decades of meticulous work to making xenotransplantation 
a clinical reality. Today, the current climate of xenotransplantation is rich. Though it is 
my hope that the present work enhances the bright landscape of xenotransplantation 
research, it would not be possible without the preceding years of tedious progress.  
Nuclease-editing in the porcine genome has facilitated our ability to create and 
study models of porcine-to-human xenotransplantation at an unprecedented pace. Chapter 
four describes combination of gene-deletions that creates a pig now within the 
immunologic standards of donor-recipient compatibility established by clinical 
allotransplantation. This animal has created a paradigm shift for the study of porcine-to-
human xenotransplantation, solidifying the merits of pursuing antigen-reduction by 
glycome modification. Although devotion to antigen-reduction represents a divergence 
from the previously-popular strategy of transgene insertion, steadfast pursuit of gene-
deletion provided the central foundation upon which the present body of work is built. 
The unpopularity of this approach has most likely indebted to its unique potential for 
failure; as outlined in chapter three, not all gene-deletion trials are successful in reducing 
human-anti-porcine immunogenicity. However, dedication to this strategy ultimately 
proved fruitful and -as described within this work- surpassed the clinical relevance of 
traditional transgenic approaches.    
Similarly, the present body of work is indebted to the current climate of progress 
within the field of genetic engineering.  As outlined within chapter one, the present 
research adds to a growing body of work that makes the manipulation of mammalian 
genomes increasingly accessible. Although positioned within our study of 
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xenotransplantation, glycobiology and immunology, it is my hope that the durability of 
this research will reach beyond the fields to which we aimed our inquiry.  The ability to 
create and select for multiple mutational events simultaneously, as well as the ability to 
control these events at the base-pair or whole gene level should be universally applicable 
across genomes. 
 
One of the greatest achievements in transplant medicine was the early adoption of 
calcineurin inhibitors; by controlling the early immunologic injury, Dr Starzl used 
tacrolimus to catalyze allotransplantation into a reliable treatment. Now a benchmark in 
transplant immuno-suppression, these macrolide lactones were first isolated from the 
bacterium Streptomuces tsukubanesis in Japanese soil. Perhaps ironically, the present 
body of work is greatly indebted to products of a similar prokaryotic genus; as discussed 
in chapter one, CRISPR/Cas9 traces its origins to Streptococcus thermophilus. The 
central aim of the present body of work is that we may soon recognize nuclease-based 
genetic engineering as the catalyst that turns xenotransplantation into a clinical reality.  
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Alpha Omega Alpha- Member since 2017 
The Society for Surgery of the Alimentary Tract. – Member since 2013 
-Elected  Member of SSAT Resident Education Committee May 2014-present. 
American Association of Transplant Surgeons- Member since 2013 
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